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Part 1  
Introduction and rationale 
 
Vitamin D deficiency has achieved, in the last years, a dramatic prevalence in Western counties, 
ranging over 50% of prevalence in the population, (1), as a consequence of pollution, the 
progressive ageing and the increased frequency of chronic disorders as renal failure. 
Vitamin D is a fat-soluble vitamin, representing not only the principal modulator of calcium and 
bone homeostasis, but also a key-hormone, regulating the transcription of about 2,000 to 8,000 
genes (2). 
Recent attention has been addressed to the cardiovascular effects of vitamin D, (3), modulating 
function, proliferation and differentiation of cardiomyocytes, endothelial cells, vascular 
musculature and the immunity processes involved in the regulation of cardiovascular health. In fact, 
hypovitaminosis D has been involved in the pathogenesis of hypertension, diabetes mellitus, 
metabolic disorders, but it has also been associated to ventricular hypertrophic remodelling, 
vascular wall degeneration and its athero- thrombotic complications (4,5).  
Different studies and a recent meta-analysis have demonstrated the clear negative prognostic 
impact of vitamin D deficiency on all-cause and cardiovascular mortality, (6), showing an inverse 
linear relationship with an increase in cardiovascular risk for every 10 ng/ml reduction in 25(OH)D. 
However, clinical trials providing vitamin D supplementation have failed to demonstrate any 
significant benefit in cardiovascular outcomes (7). Several explanations have been provided for such 
findings, including inadequate study design and factors modulating vitamin D repletion or 
differential activation. In fact, the majority of the studies so far conducted were not powered for 
the evaluation of cardiovascular endpoints, and moreover the therapeutic strategy was insufficient 
        
for the restoration of adequate levels of vitamin D, therefore rendering inconclusive the majority of 
the data. 
Moreover, particular attention has been focused on the role of genetics, that could modulate the 
transportation and the systemic levels of vitamin D, but also its transformation to the hydroxylated 
form, with hormonal effect. In fact, two common genetic variants of the Vitamin D Binding Protein 
(VDBP), vitamin D transporter, have been held responsible for more than 10% of the interindividual 
variability in the circulating levels of 25(OH)D, conditioning its bioavailability and peripheral effects 
(8). In fact, the variations in the DBP originally referred to as GC1F, GC1S, and GC2 were first 
reported more than 50 years ago and can condition its affinity for 25(OH)D and, therefore, the 
quote of “free” functional vitamin. 
In addition, five single nucleotide polymorphisms have been described for vitamin D receptor (VDR), 
partially combined among them in consequence of linkage disequilibrium, to generate specific 
haplotypes with consequences on the receptor’s signaling and effects (9).  
Among these variants, Cdx and GATA are located at the promoter of the gene, controlling the 
transcription of the receptor and then the effectiveness of calcitriol signaling, FokI is responsible of 
a change in the coding region, conditioning the binding of vitamin D to VDR,  whereas the variants 
BsmI, ApaI e TaqI fall in the 3’UTR of the gene, potentially conditioning the stability of the mRNA 
and then the achievement of the transcription product (10). BsmI, in particolar, has been positively 
linked to cardiovascular risk, causing a loss of the cardioprotective effects of vitamin D and a 
disregulation in the transformation of  vitamin D into its active form. In fact, the complex vitamin D- 
VDR controls the inhibition of CYP27B1 (the 1-α hydroxylase activating vitamin D) and activates 
CYP24A1 (the 24-α hydroxylase responsible for the degradation of activated calcitriol). 
        
Moreover, genetic variants of these hydroxylation enzymes have been described, potentially 
modulating the levels of the activated 1,25(OH)2D and therefore the final action of the hormone, 
although their impact on vitamin D signaling is still matter of debate (11).   
A more intriguing hypothesis, however, recently proposes that many effects of 25(OH)D could be 
the consequence of a local, autocrine or paracrine activation of vitamin D (12). Such kind of 
production derives from the differential expression of CYP27B1 in different cells types, as 
endothelial cells, myocytes, cardiomyocytes and macrophages, that can generate a transient and 
local increase in the intravascular concentrations of activated vitamin D (13).  
In effect, Dickie et al. have demonstrated that the release of pro-inflammatory cytokines can induce 
an autocrine/paracrine production of 1,25(OH)2D in macrophages and lymphocytes attracted to 
the inflammation site, resulting in a reduction of inflammation and a preferential production of 
anti-infiammatory factors as IL4 or IL10, that stimulate the T reg e Th2 lymphocytes (14). This 
mechanism has been proposed to explain how 1,25(OH)2D can prevent the production of foam 
cells in diabetic patients, contrasting the generation of the atheromasic plaque (15).  
Nevertheless, the cardiovascular impact of the differential homeostasis of vitamin D is poorly 
understood. Anyhow, a relevant role could be hypothesized especially in the context of acute 
coronary syndromes or among patients undergoing percutaneous coronary interventions. In fact 
the pro-thrombotic, pro-inflammatory and pro-oxidant setting might enhance the importance of 
the activity of vitamin D, both at a local level and for its systemic implications, modulating platelet 
reactivity and circulating cytokines. In addition, no study has so far addressed of 1,25(OH)2D in 
coronary artery disease (CAD).  
In the present thesis we will confirm and re-assess the mechanisms involving hypovitaminosis D in 
the pathogenesis of atherosclerosis and in the regulation of platelet hyper-reactivity and 
thrombotic risk, with a focus on those genetic factors that could condition the interindividual 
        
difference in its bioavailability and effectiveness. In addition, we will assess the relationship 
between the levels of 25(OH)D and 1,25(OH)2D, attempting to identify those clinical and genetic 
the determinants of the activation of vitamin D, trying to provide new targets for the therapeutic 
strategies of supplementation and shed light on the reasons for negative findings of previous trials 
with vitamin D.    
 
 
 
References 
1. Lavie CJ, DiNicolantonio JJ, Milani RV, O’Keefe JH. Vitamin D and Cardiovascular Health. Circulation. 2013;128:2404-2406. 
2. Gil Á, Plaza-Diaz J, Mesa MD. Vitamin D: Classic and Novel Actions. Ann Nutr Metab. 2018;72(2):87-95 
3. Verdoia M, Schaffer A, Sartori C, Barbieri L, Cassetti E, Marino P, Galasso G, De Luca G. Vitamin D deficiency is independently associated 
with the extent of coronary artery disease. Eur J Clin Invest. 2014;44(7):634-42 
4. Kunadian V, Ford GA, Bawamia B, Qiu W, Manson JE. Vitamin D deficiency and coronary artery disease: A review of the evidence.  Am 
Heart J 2014;167:283-91 
5. Stach K, Kalsch AI, Nguyen XD, et al. 1alpha,25-dihydroxyvitamin d3 attenuates platelet activation and the expression of vcam-1 and mt1-
mmp in human endothelial cells. Cardiology 2011;118:107-15 
6. Wang C. Role of vitamin d in cardiometabolic diseases. J Diabetes Res. 2013;2013:243934 
7. Mao Mao PJ, Zhang C, Tang L, Xian YQ, Li YS, Wang WD, Zhu XH, Qiu HL, He J, Zhou YH. Effect of calcium or vitamin D supplementation on 
vascular outcomes: a meta-analysis of randomized controlled trials. Int J Cardiol. 2013 ;169(2):106-11 
8. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR, Thadhani R. Vitamin 
D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369(21):1991-2000 
9. Fang Y, van Meurs JB, d’Alesio A, Jhamai M, Zhao H, Rivadeneira F, Hofman A, van Leeuwen JP, Jehan F, Pols HA & Uitterlinden AG. 
Promoter and 30-untranslated-region haplotypes in the vitamin D receptor gene predispose to osteoporotic fracture: the Rotterdam 
study. American Journal of Human Genetics 2005 ; 77 :807–823 
10. De Jongh RT, Lips P, Rijs JK, van Schoor NM, Kramer NH, Vandenbroucke  JP, Dekker OM. Associations between vitamin D receptor 
genotypes and mortality in a cohort of older Dutch individuals. European Journal of Endocrinology, 164: 75–82 
11.  Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, Kritchevsky SB et al. Genetic Variants and Associations of 25-
Hydroxyvitamin D Concentrations With Major Clinical Outcomes 
12. Richart T, Li Y, Staessen JA. Renal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and 
hypertension. Am J Hypertens. 2007;20:1007–1015 
13.  Norman PE, Powel JT. Vitamin D and Cardiovascular Disease. Circ Res. 2014;114:379-393 
14. Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF. Vitamin D3 down-regulates intracellular Toll-like receptor 9 
expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford). 2010;49:1466–1471. 
15. Riek AE, Oh J, Sprague JE, Timpson A, de las Fuentes L, Bernal- Mizrachi L, Schechtman KB, Bernal-Mizrachi C. Vitamin D suppression of 
endoplasmic reticulum stress promotes an antiatherogenic monocyte/macrophage phenotype in type 2 diabetic patients. J Biol Chem. 
2012;287:38482–38494 
 
 
Part 2 
   
 
 
 
 
Vitamin D in coronary artery disease 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: 
Vitamin D deficiency is independently associated with the extent of coronary 
artery disease 
Monica Verdoiaa, MD, Alon Schaffera, MD, Chiara Sartoria, MD, Lucia Barbieria, MD, Ettore Cassettia, 
MD, Paolo Marinoa, MD, Gennaro Galassob, MD, PhD; Giuseppe De Lucaa, MD, on behalf of the 
Novara Atherosclerosis Study Group (NAS) 
aDepartment of Cardiology, Ospedale “Maggiore della Carità”, Eastern Piedmont University, Novara, Italy; b 
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy 
Eur J Clin Invest. 2014 Jul;44(7):634-42 
Abstract  
Background. Vitamin D (25-OH D3) deficiency represents a rising social and economic problem in 
Western countries. Vitamin D has been recently reported to modulate inflammatory processes, 
endothelium and smooth muscle cell proliferation and even platelet function, thus potentially 
modulating atherothrombosis. Great interest has been addressed on its impact on cardiovascular 
outcome, with contrasting results. The aim of current study was to evaluate the relationship between 
25-OH D3 and the extent of coronary artery disease in a consecutive cohort of patients undergoing 
coronary angiography.  
Methods. Patients undergoing elective coronary angiography were included in a cross-sectional 
study. Fasting samples were collected for 25-OH D3 levels assessment. Significant CAD was defined 
as at least 1 vessel stenosis > 50%, while severe CAD as left main and/or trivessel disease, as evaluated 
by Quantitative Coronary Angiography.  
Results. Hypovitaminosis D was observed in 70.4 % out of 1484 patients. Patients were divided 
according to vitamin D tertiles (<9.6; 9.6-18.4; >18.4). Lower vitamin D levels were associated with 
age, female gender (p<0.001, respectively), renal failure (p=0.05), active smoking (p=0.001), acute 
coronary syndrome at presentation (p<0.001), therapy with calcium-antagonists (p=0.02) and 
diuretics (p<0.001), less beta-blockers (p=0.02) and statins (p=0.001) use. Vitamin D directly related 
to haemoglobin (p<0.001) and inversely with platelet count (p=0.002), total and LDL cholesterol 
(p=0.002 and p<0.001) and triglycerides (p=0.01). Vitamin D did not influence angiographic features 
of coronary lesions, but was associated with higher prevalence of left main or right coronary artery 
disease (p=0.03). Vitamin D deficiency was significantly associated with higher prevalence of CAD 
(adjusted OR[95%CI]=1.32[1.1-1.6],p=0.004) and severe CAD (adjusted OR[95%CI]= 1.18[1-1.39], 
p=0.05).  
 Conclusion. In patients undergoing coronary angiography hypovitaminosis D was observed in the vast 
majority of patients. Vitamin D deficiency is significantly associated with the prevalence and extent 
of CAD, especially for patients with values < 10 ng/ml. Therefore, future large studies are needed to 
evaluate whether vitamin D supplementation may prevent CAD and its progression. 
Keywords: vitamin D, coronary artery disease; coronary angiography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
Cardiovascular disease represents the leading cause of mortality in developed countries. Great 
reduction in mortality has been achieved by improvement in myocardial revascularization techniques 
(1,2), however, the results are still unsatisfactory in high-risk subgroups. Therefore, large interests 
have been focused on the identification of new risk factors for Coronary Artery Disease (CAD) (3) and 
its prevention.  
Calcium metabolism disorders, and in particular vitamin D (25-hydroxy -cholecalciferol,  25-OHD3) 
deficiency, represent a rising problem, whose social and economic impact is growing due to aging of 
the population. Vitamin D has received, in the last few years,  great interests for its multiple effects 
on inflammatory system and potential role in atherothrombosis. Hypovitaminosis D has been related 
to endothelial dysfunction and enhanced risk of cardiovascular disease (4-6). In fact, Vitamin D 
receptor has been identified on the surface of smooth muscle cells  (7), endothelial cells and 
cardiomyocytes, but also on inflammatory cells, controlling their proliferation and differentiation (8), 
and even in platelets, thus potentially influencing thrombosis (9). Furthermore, independent 
association has been demonstrated between vitamin D deficiency and cardiovascular risk factors, 
such as hypertension (10), diabetes mellitus (11), obesity (12), metabolic syndrome(13). These 
associations may contribute to explain the observed relationship between vitamin D and 
atherosclerosis. The aim of the present study is to evaluate the relationship between 25-OH D3 and 
the extent of CAD in a consecutive cohort of patients undergoing coronary angiography. 
Methods                           
Consecutive patients undergoing coronary angiography between September 2009 and June 2013 at 
the Ospedale “Maggiore della Carità”, Novara, Italy were eligible to participate in a cross-sectional  
study. Informed consent before angiography was the only required inclusion criterium. Patients 
receiving vitamin D supplementation at admission or those whose vitamin D status was unavailable 
were excluded. The study was approved by our local Ethical Committee. All demographic and clinical 
data were prospectively collected in a dedicated database. Hypertension was defined as systolic 
pressure > 140 mm Hg and/or diastolic pressure > 90 mm Hg or if the individual was taking 
antihypertensive medications (14). Diabetes mellitus was defined as previous diagnosis, specific 
treatment administration (oral drug or insulin),  fasting glycaemia > 126 mg/dL or HbA1c > 6.5%. 
Chronic renal failure was considered for history of renal failure or an admission glomerular filtration 
rate (GFR) < 60 mol/min/1.73m2 by MDRD (Modification of Diet in renal Disease) formula.  
Biochemical measurements   
Blood samples were drawn at admission in patients undergoing elective (following a fasting period of 
12 h) or urgent coronary angiography. Glucose, creatinine, glycosylated haemoglobin and lipid profile 
were determined by standard methods. Vitamin D dosing was performed by chemiluminescence 
method through LIAISON® Vitamin D assay (Diasorin Inc). The normal range for 25-OH D3 levels in 
our laboratory is from 30 to 100 ng/ml, according to literature reference (15).  Severe 
hypovitaminosis D was considered for values < 10 ng/ml as previously reported (16). 
Coronary angiography                                                  
 Coronary angiography (carried our by Siemens AXIOM ARTIS dTC, Erlangen, Germany) was routinely 
performed by the Judkins technique using 6-French right and left heart catheters. Quantitative 
coronary angiography was performed by two experienced interventional cardiologists who had no 
knowledge of the patients' vitamin D status, by an automatic edge-detection system for Quantitative 
Coronary Angiography (Siemens Acom Quantcor QCA, Erlangen, Germany) (17)). After a visual 
inspection of the coronary artery, the frame of optimal clarity was selected, showing lesion at maximal 
narrowing and arterial silhouette in sharpest focus. After the calibration of guiding catheter, analysed 
arterial segment with coronary lesion was defined by moving the cursor from the proximal to the 
distal part of coronary artery to ensure adequate determination of reference diameter. Minimal 
luminal diameter, reference diameter, percent diameter stenosis, and length of the lesion were 
measured. Significant CAD was defined as the presence of at least 1 coronary stenosis more than 
50%. Severe CAD was defined as the presence of three-vessel disease and/or left main disease. For 
patients who had previously undergone percutaneous coronary interventions, the treated lesion was 
considered as significantly diseased vessel. In previously bypassed patients, both native arteries and 
grafts were taken into account in the evaluation of extension of coronary artery disease (number of 
diseased vessels). 
Statistical analysis   
Statistical analysis was performed using SPSS 17.0 statistical package. Continuous data were 
expressed as mean + SD and categorical data as percentage. Analysis of variance and the chi-square 
test were used for continuous and categorical variables, respectively. Patients were grouped 
according to tertiles of Vitamin D. A trend analysis was performed as previously described (18). In 
particular, we used polynomial contrasts in case of a continuous variable, whereas we assessed the 
linearity assumption by including new variables (the upper three quartiles vs. the lowest quartile of 
vitamin D) in the regression model and plotting the estimated logistic regression coefficients versus 
the quartile midpoints of vitamin D in case of a categorical variable. Multiple logistic regression 
analysis was performed to evaluate the relationship between 25OH-D3 and CAD, after correction for 
baseline confounding factors (all baseline characteristics that significantly (p value < 0.05) differed 
between groups), that were entered in the model in block. Log-transformation was applied to non-
normally distributed variables (as evaluated by the Kolmogorov-Smirnov test) before entering into 
the logistic regression model. A p value < 0.05 was considered statistically significant.   
 
 
 
Table 1. Clinical characteristics according to Vitamin D tertiles 
 
Baseline clinical characteristics 
I tertile 
< 9.6 
N= 482 
II tertile 
9.6-18.4 
N= 495 
III tertile 
≥ 18.4 
N= 507 
P value 
Age (mean±SD) 68.9±12 66.8±11.4 67.4±11.3 <0.001 
Male Sex (%) 62 74.7 74.4 <0.001 
Hypercholesterolemia(%) 59.5 57.7 54.9 0.33 
Diabetes mellitus (%) 36.9 32.3 33.3 0.29 
Renal failure (%) 18.9 10.1 14.4 0.05 
Family history of CAD (%) 25.9 30.4 32.1 0.13 
Smokers (%)    0.001 
Active smokers (%) 24.8 23.2 16.6  
Previous smokers (%) 19.9 24.6 28.8  
Hypertension (%) 75.6 71.9 72.9 0.39 
History of MI (%) 23.4 23.4 20.3 0.25 
Previous PCI (%) 23.6 28.4 28.2 0.17 
Previous CABG (%) 13.4 9.1 11.1 0.26 
Previous CVA (%) 7.4 4.9 5.3 0.18 
Indication to angiography    <0.001 
Stable angina/ silent ischemia (%) 14.8 23.2 27.3  
STEMI/ACS (%) 61.5 60.2 56.9  
Other (%) 23.7 16.6 15.7  
ACE inhibitors(%) 38.1 38.3 33.7 0.15 
ARB (%) 22.5 19.2 21.7 0.75 
Beta blockers (%) 47 52.5 54.3 0.02 
Nitrates (%) 31.1 31.7 32.1 0.74 
Statins (%) 41.5 51.8 52.7 0.001 
Calcium antagonists (%) 23 17.8 17.2 0.02 
Diuretics (%) 37.6 27.7 23.2 <0.001 
ASA (%) 54.4 58.5 59.4 0.11 
Clopidogrel (%) 17.2 19.4 20.5 0.65 
Biochemistry parameters     
Platelets (10^6/ml; mean± SD) 226.8±81.4 218±59.8 211.7±61.3 0.002 
Haemoglobin ( g/dl) 13.1±1.8 13.5±1.6 13.6±1.6 <0.001 
WBC (10^3/ml;mean± SD) 8±2.7 7.9±2.4 7.6±2.7 0.08 
HDL cholesterol (mg/dl) 42.7±13.4 43.3±12.8 43.9±13.6 0.39 
Total cholesterol (mg/dL) 169.7±45.1 163.1±42.8 160.3±37.6 0.002 
LDL cholesterol (mg/dL) 101.5±46.1 93.7±38.6 91.8±33.7 <0.001 
Triglycerides (mg/dl) 141.7±95.5 136.9±78.6 126.6±70.4 0.01 
Glycaemia (mg/dL) 127.2±55.9 123.4±50.2 123.4±40.2 0.27 
Creatinine (mg/dL) 1.1±0.82 1.05±0.68 1.1±0.72 0.48 
 
CAD = Coronary Artery Disease; MI = Myocardial Infarction; CVA = Cerebrovascular Accident; PCI = Percutaneous Coronary Interventions; CABG = 
Coronary Artery Bypass Grafting; STEMI = ST-Elevation Myocardial Infarction; ACS = Acute Coronary Syndrome; CMD =Dilated Cardiomyopathy; LV = 
Left Ventricle; EF = Ejection Fraction; ACE = Angiotensin Converting Enzyme; ARB = Angiotensin Receptor Blockers; ASA = Acety lsalicylic Acid; LDL = 
Low-Density Lipoproteins.  
Results 
Between September 2009 and June 2013, 1509 patients underwent coronary angiography at our 
institution. Among them, 25 patients were taking chronic vitamin D supplementation and were 
therefore excluded. Thus, 1484 patients were enrolled.  
Hypovitaminosis D (< 20 ng/mL) was observed in 1045 patients, (70.4% of the total population). 
Vitamin D levels underwent seasonal variation, with significant differences (p<0.001) between 
spring/summer months (April to September, 18.05 ± 11ng/mL) as compared with autumn/winter 
(October to March, 13.6 ± 8.3 ng/mL) months.  
Patients were divided in three groups according to tertiles of Vitamin D (< 9.6, 9.6-18.4, > 18.4 ng/mL, 
respectively). Baseline demographic and clinical characteristics of the three groups are shown in 
Table 1. Vitamin D was associated to age (p<0.001), female gender (p<0.001), renal failure (p=0.05), 
active smoking (p=0.001), presentation with acute coronary syndrome (p<0.001), therapy at 
admission with calcium-antagonists (p=0.02) and diuretics (p<0.001), as well as with less frequent 
use of beta-blockers (p=0.02) and statins (p=0.001). Vitamin D directly related with haemoglobin 
levels (p<0.001) and inversely with platelet count (p=0.002), total and LDL cholesterol (p=0.002 and 
p<0.001, respectively) and triglycerides (p=0.01).  
Table 2 displays main angiographic features, that did not differ according to vitamin D levels, with the 
exception of higher prevalence of left main (p=0.03) or right coronary artery disease (p=0.03).  
No significant difference was found between vitamin D deficiency tertiles and general coronary artery 
disease prevalence (79.1% vs 75.8 % vs 75.4%; p=0.17, OR [95%CI]= 1.11[0.96-1.28], p = 0.18), as 
depicted in Figure 1A. However, as shown in Figure 1B, lower vitamin D deficiency tertiles were 
significantly associated with a higher prevalence of severe coronary artery disease (34.4% vs 27.3% 
vs 27.0%, p = 0.01, OR[95%CI] = 1.19 [1.04-1.37], p = 0.01).  
 
Table 2. Angiographic characteristics according to Vitamin D tertiles (per lesion) 
Angiographic features 
I tertile 
< 9.6 
N= 904 
II tertile 
9.6-18.4 
N= 845 
III tertile 
≥ 18.4 
N= 819 
P value 
Left main disease (%)§ 13.2 9.3 9 0.03 
LAD (%)§ 54.3 55.1 54.1 0.94 
CX (%)§ 39.8 41.5 41.7 0.56 
RCA (%)§ 50.4 46.7 43.9 0.03 
Type C Lesion (%) 32 32.8 33.8 0.41 
Lesion length (mm) 20.9±13.9 22±13.4 21.7±12.7 0.27 
Percent stenosis (%)   86±14.9 86.8±13.2 87.2±13.8 0.54 
Reference Diameter (mm) 2.9±0.89 3±2.2 2.9±1.2 0.26 
Proximal vessel tortuosity (%) 1.6 1.8 2.1 0.43 
Calcifications (%) 20.3 21.6 18.5 0.38 
Chronic occlusion (%) 19 15.1 16.6 0.18 
Restenosis (%) 3 5.8 4.3 0.17 
Thrombus (%) 3.4 4.7 3.3 0.64 
TIMI Flow      0.83 
3 68.9 71.5 70.7  
2 8 7.1 5  
1 4.2 3.3 3.3  
0 18.9 18.1 21  
§ Per patient definition 
LAD= Left Anterior Descending coronary artery; Cx= Circumflex coronary artery; RCA= Right Coronary Artery; TIMI= Thrombolysis  in Myocardial 
Infarction;  
 
Figure 1. Bar graphs showing the relationship between vitamin D tertiles values and the prevalence of coronary artery 
disease (CAD) Figure 1A (upper graph), and between vitamin D levels and the prevalence of  severe left main/trivessel 
coronary artery disease (CAD), Figure 1B, (lower graph), *= p<0.05 for comparison of I vs II tertile, **= p<0.05 for I vs III 
tertile.  
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Figure 2. Bar graph showing vitamin D levels in patients with or without coronary disease (2A, upper graph) and severe 
left main and/or trivessel coronary artery disease (2B, lower graph). 
 
 
 
 
 
 
 
 
 
After adjustment for baseline characteristics (age, gender, renal failure, smoking, acute presentation, 
calcium-antagonists, diuretics, beta-blockers, statins, haemoglobin, platelet count, total and LDL 
cholesterol, triglycerides), the association between low vitamin D levels and CAD reached a statistical 
significance (adjusted OR [95%CI] = 1.32[1.1-1.6], p = 0.004), that was confirmed also for severe CAD 
(adjusted OR [95%CI] = 1.18 [1-1.39], p = 0.05). We additionally analyzed the association between 
CAD and Vitamin D as continuous variable. As shown in Figure 2, vitamin D levels were significantly 
lower in CAD patients (15.4± 9.2 vs 16.7±12 ng/mL, p=0.03, Figure 2A) and patients with severe CAD 
(14.7± 9.2 vs 16.1±10.2, p= 0.01, Figure 2B).   
Moreover, the results were confirmed when comparing the extent of coronary atherosclerosis with 
the severity of vitamin D deficiency (severe deficiency- < 10 ng/ml, n = 510;  mild  to moderate 
deficiency -10 to 20 ng/ml-, n = 535). In fact, patients with severe hypovitaminosis showed a non-
significant higher prevalence of coronary artery disease (p=0.20, Figure 3A). At multivariate analysis, 
comparing hypovitaminosis D patients to patients with normal vitamin D status, although no 
significant association was found between mild hypovitaminosis D and coronary artery disease 
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(adjusted OR[95%CI]=1.2[0.83-1.72], p=0.34), a statistically significant association was identified 
between severe hypovitaminosis D and prevalence of coronary artery disease (adjusted 
OR[95%CI]=1.73[1.18-2.52], p=0.005).  
As shown in Figure 3B, a significant relationship was observed between Vitamin D levels and severe 
CAD. However, only severe Hypovitaminosis D (adjusted OR[95%CI]=1.37[1.001-1.89], p=0.05), but 
not mild-to-moderate hypovitaminosis D (OR[95%CI]=1.28[0.93-1.76], p=0.13) showed a significantly 
higher rate of CAD as  compared to patients with normal Vitamin D  status. 
Figure 3. Bar graphs showing the relationship between the severity of vitamin D deficit and the prevalence of coronary 
artery disease (CAD) Figure 3A (upper graph), and between hypovitaminosis D severity and the prevalence of severe left 
main/3-vessel coronary artery disease (CAD), Figure 3B, (lower graph), *= p<0.05 for severe deficiency vs normal values.  
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The main finding of the present study is a significant association between 25-OH D3 and the 
prevalence of severe coronary artery disease. Furthermore, patients with at least 1 coronary stenosis 
more than 50% had significantly lower vitamin D status than patients undergoing coronary 
angiography who did not had a significant coronary artery disease.  
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Despite the great improvement of revascularization techniques and antithrombotic therapies  for the 
treatment of CAD the results are still unsatisfactory in high-risk subgroups of patients (19). Therefore, 
great efforts have been done in the last years in order to identify potential new risk factors to prevent 
and improve outcome of patients with CAD.  
Vitamin D is a kind of fat-soluble pro-hormone, that can be introduced both with diet or produced in 
the skin through the effect of sun UV rays. It is transformed into active form by a first hepatic 
hydroxylation in 25-position (25-OH D3) and a successive 1-position renal hydroxylation; 25-OH D3 
has a 2-3 weeks half-life and its concentration is dependent on levels of new produced hormone. For 
several reasons much interest has been focused in the last decade on its involvement in the 
atherosclerotic process. In fact, vitamin D replacement therapy is a very cheap therapeutic strategy 
(20). Furthermore, Vitamin D deficiency is a rising, widespread endemic problem, especially in 
Western counties, due to ageing of the population, with decreasing capability of 25-OH D3 synthesis 
(21), and reduced outdoors living (22), as lower levels of vitamin D have been reported in the elderly, 
in female gender and in patients with renal failure (234), that are well-established subgroups of 
patients at high cardiovascular risk. Moreover, hypovitaminosis D has been recently linked to the 
etiology of hypertension and to a multitude of adverse cardiovascular outcomes (4,6,10), as vitamin 
D has been reported to modulate endothelial function, inflammatory processes, (244-27), and 
potentially  thrombotic events (28). However, the involvement of vitamin D in the development of 
atherosclerosis is still debated.  
Serum levels of vitamin D have been shown to be inversely associated with the extent of vascular 
calcifications (29-31) and with carotid intima-media thickness (32), which represent early markers of 
atherosclerosis. In the large Multi-Ethnic Study of Atherosclerosis (MESA), including 6436 patients 
with CAD, followed for over 8 years, lower serum 25-OH D3 concentration was associated with an 
increased risk of incident cardiovascular events among white race participants (33). In addition, 
Shanker et al. reported in 287 patients with CAD, vitamin D levels to be significantly lower than in 
matched healthy controls, with patients in the first vitamin D quartile having a 2.54 times greater risk 
for CAD than those in the fourth quartile (34). 
More recently, Goleniewska et al. evaluating 130 patients with ST-elevation myocardial infarction, 
identified vitamin D levels as independent predictors of multivessel CAD at multiple stepwise logistic 
regression (35). 
However, data from the combined National Health and Nutrition Examination Survey (NHANES) 2001 
to 2006, a population-based cross-sectional study, and the NHANES III cohort, a population-based 
cohort study, showed that the associations of serum 25(OH)D with mortality, particularly due to 
cardiovascular disease (CVD) and colorectal cancer, were modified by magnesium intake. In fact, the 
inverse associations were primarily present among those with magnesium intake above the median 
(36). 
To the best of our knowledge, this represents the first large study investigating the relationship 
between vitamin D levels and the extent of coronary artery disease as evaluated by coronary 
angiography. In our population we confirmed the clinical relevance of hypovitaminosis D, that was 
present in the majority of patients, with seasonal variations form modest to severe deficiency, 
although still remaining in the range of hypovitaminosis D.  
In our study, we identified a significant association between low levels of 25-OH D3 and major risk 
factors for CAD such as age, female gender, renal failure, hypercholesterolemia, anaemia and 
smoking, which certainly played a relevant role on our results. In fact, the association between 
vitamin D deficiency and the extent of CAD resulted statistically significant only after correction for 
baseline differences. Moreover, a continuous effect of decreasing vitamin D levels and coronary 
disease can be suggested from our results, as more severe CAD (including left main disease) was 
found especially in presence of severe D hypovitaminosis, thus suggesting that patients with vitamin 
D values < 10 ng/ml should be regarded as those at higher potential cardiovascular risk.  
However, no difference was found in terms of angiographic features, like the presence of calcified 
lesions or intracoronary thrombus, thus suggesting multiple vascular effects of vitamin D, not being 
mediated just by one preferred pathway. Despite this clinical evidence, contrasting results have been 
reported so far with cholecalciferol supplementation. In a randomized trial Witham et al (37) found 
that one single high-dose load of vitamin D2 improved endothelial function, defined as flow-mediated 
dilatation of the brachial artery. These beneficial effects have been confirmed by Sugden et al. (38) 
who demonstrated endothelial function improvement in diabetics after vitamin D administration. 
However, Sokol et al (39) failed to confirm any change in proinflammatory cytokine levels and 
endothelial function after cholecalciferol repletion in 90 CAD patients. Finally, a recent systematic 
review and meta-analysis was unable to demonstrate a statistically significant reduction in mortality 
and cardiovascular risk, including stroke and myocardial infarction, with vitamin D supplementation 
(40). However, most of these trials were not focused on cardiovascular prevention and did not select 
patients at higher risk of cardiovascular events, but were mostly focused on the prevention of bone-
fracture complications. Therefore, future dedicated larger trials are certainly needed to further 
investigate the effects of vitamin D supplementation on cardiovascular prevention and 
atherosclerotic disease progression in high-risk patients.  
LIMITATIONS 
The present study was observational. Thus, causal relationship could only be postulated, but not 
proved. Furthermore, no information on long-term effects of vitamin D levels can be derived from 
this study, as we did not collect follow-up data. However, previous studies evaluating fetal and early 
life vitamin D deficiency revealed an impact on vulnerability to cardiovascular disease in adulthood 
at a very extended follow-up (41). 
Diet, as much as the differences in pharmacological therapy at admission, could have influenced our 
results, as patients with lower levels of vitamin D were receiving less often statins and beta-blockers, 
thus potentially increasing their cardiovascular risk. However, our findings were confirmed even at 
multivariate analysis after correction for potential baseline confounders.  
Moreover, the present data are derived from only one region of Northern Italy, and from patients 
included at only a single academic hospital. Therefore, the results might not be automatically 
generalized to other populations. In fact, larger vitamin D levels variations could have been identified 
if the study had been conducted in a different geographical region, allowing more extended sun 
exposure.  
Some results did not reach statistical significance. This could simply reflect the reality or, alternatively, 
be due to study limitations, such as the classification in tertiles, a relatively small sample size or the 
presence of several confounding factors. Furthermore, non-calciotropic protective effects on 
atheroscelerosis may be potentially observed at higher concentrations as compared to calciotropic 
effects. Finally, there might be some additional factors that we did not explore, such as Vitamin D 
receptor polymorphisms and levels of Vitamin D binding protein (42). 
The use of intravascular ultrasound would have probably improved the results of the current study, 
as it may provide more accurate information on the amount of coronary atherosclerotic plaque and 
extent of coronary atherosclerosis, as compared to coronary angiography. In addition, since the aim 
of the study was to evaluate the extent of coronary artery disease, in order to avoid a potential 
selection bias, patients undergoing angiography for valvular disease or dilated cardiomyopathy as 
primary indication were not excluded, due to the possible presence of a concomitant coronary artery 
disease. We were unable to explain whether Vitamin D  could play a role in the development of a 
site-specific coronary atherosclerosis, and in particular the higher prevalence of right coronary artery 
disease observed  in patients with low vitamin D levels, that may potentially be due to a play of 
chance.  
CONCLUSIONS 
In patients undergoing coronary angiography severe hypovitaminosis D is frequent, being found 
among most of the investigated subjects. Furthermore, seasonal variation of vitamin D levels was 
found. Vitamin D deficiency is significantly associated with the severity of coronary artery disease, 
defined as left main and/or trivessel disease. Furthermore, patients with significant coronary artery 
disease had significantly lower vitamin D status than patients who did not show significant stenosis 
at angiography. The association was stronger for patients with vitamin D levels <10ng/mL. Therefore 
additional studies are needed to evaluate the potential benefits of vitamin D supplementation on the 
prevention of CAD and its progression.   
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Abstract  
Background. Statins represent a pivotal treatment in coronary artery disease, offering a reduction in 
cardiovascular risk even beyond their lipid-lowering action. However, the mechanism of these 
“pleiotropic” benefits of statins are poorly understood. Vitamin D has been suggested as a potential 
mediator of the anti-inflammatory, anti-thrombotic and vascular protecting effects of statins. Aim of 
present study was to assess the impact of a high-intensity statin therapy on vitamin D levels and 
platelet function in patients with coronary artery disease.  
 
Methods. Patients discharged on dual antiplatelet therapy and high-intensity statins after an ACS or 
elective PCI were scheduled for main chemistry and vitamin D levels assessment at 30-90 days post-
discharge. Vitamin D (25-OHD) dosing was performed by chemiluminescence method through 
LIAISON® Vitamin D assay (Diasorin Inc). Platelet function was assessed by Multiplate® (multiple 
platelet function analyser; Roche Diagnostics AG).  
 
Results. Among 246 patients included, 142 were discharged on a new statin therapy or with an 
increase in previous dose (Inc-S), while 104 were already receiving a high-dose statin at admission, 
that remained unchanged (eq-S). Median follow-up was 75.5 days. Patients in the Inc-S group were 
younger (p=0.01), smokers (p<0.001), with a lower history of hypercholesterolemia (p=0.05), 
diabetes (p=0.03), hypertension (p=0.02), or previous cardiovascular events (p<0.001). They were 
more often admitted for an acute coronary syndrome (p<0.001) and used less frequently anti-
hypertensive drugs or nitrates.  Higher total circulating calcium was observed in the Inc-S group 
(p=0.004), while baseline vitamin D levels were similar in the 2 groups (p=0.30). A significant 
reduction in the circulating low-density lipoprotein (LDL) cholesterol was observed in the Inc-S group. 
Vitamin D levels increased in the Inc-S patients but not in the eq-S group (delta-25OHD: 23.2±20.5% 
vs 3.1±4.7%, p=0.003), with a linear relationship between the magnitude of vitamin D elevation and 
the reduction of LDL cholesterol (r=-0.17, p=0.01). Platelet reactivity was significantly lower in the 
Inc-S patients, when evaluating aggregation with different platelet activating stimuli (arachidonic 
acid, p=0.02, collagen, p=0.004, thrombin-activating peptide, p=0.07, ADP, p=0.002).  
 
Conclusions. In patients with coronary artery disease, the addition of a high-intensity statin 
treatment, besides the lipid-lowering effects, is associated to a significant increase in vitamin D levels 
and lower platelet reactivity, potentially providing explanation of the “pleiotropic” benefits of statins 
therapy in cardiovascular disease.   
 
Keywords: vitamin D, statins; platelet aggregation, coronary artery disease 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
 In the era of interventional cardiology representing the first treatment option for the majority of 
patients with coronary artery disease (CAD), a crucial role in cardiovascular prevention is still played 
by pharmacological therapy (1-3). Statins, the inhibitors of cholesterol synthesis, are strongly 
recommended in all patients with coronary artery disease, having demonstrated in several trials a 
25-40% reduction in cardiovascular risk (4), directly related to the magnitude of low-density 
lipoprotein cholesterol (LDL-C) lowering (5). Moreover, a relevant regression in the volume of 
atheromasic plaque has been demonstrated with high-intensity statins, those achieving over 40% 
cholesterol reduction (6,7). However, the benefits of this therapy in CAD has been ascribed not only 
to an aggressive reduction of circulating pro-atherogenic lipid particles, but also to its “pleiotropic” 
effects, including improvement in endothelial function, anti-inflammatory and anti-oxidant actions, 
whose mechanism is still largely undefined (8,9).   
Previous reports have suggested a role of vitamin D in explaining the pleiotropic effects of statins 
(10,11). In fact, vitamin D (25-OHD) is the precursor of a hormone with a widespread cardio-
protective function, modulating inflammatory and thrombotic processes (12). Hypovitaminosis D, 
indeed, has been linked to the development of main established cardiovascular risk factors, as 
hypertension or diabetes, and to an increased risk of CAD and acute myocardial infarction (13-15). 
However, despite, in certain studies, statin administration could raise the circulating levels of 25-OHD 
in patients with dyslipidaemia or diabetes (16,17), confirming a potential vitamin D-statin interplay 
in cardiovascular prevention, results were not confirmed by other reports (18), with even few data in 
patients with established CAD.  
Therefore, aim of present study was to evaluate the impact of a high-intensity statin therapy on 
vitamin D levels and platelet function in patients with a recent acute coronary syndrome or 
percutaneous coronary interventions.  
Methods  
We included patients admitted Division of Cardiology, “Maggiore della Carità” Hospital, Università 
del Piemonte Orientale in Novara, Italy, from September 2013 to December 2014 requiring dual 
antiplatelet therapy for acute coronary syndromes or after PCI for stable coronary artery disease. 
Invasive treatment with coronary angiography and eventual coronary stenting was not a required 
inclusion criterion. All patients receiving at discharge high-intensity statins and a dual antiplatelet 
therapy with ASA (100 to 160 mg daily) and ADP-antagonist (clopidogrel 75 mg daily or ticagrelor 90 
mg b.i.d) were scheduled for chemistry and platelet function tests evaluation at 30-90 days from 
discharge.  
High-intensity statin therapy was considered for atorvastatin ≥ 20 mg/daily, rosuvastatin ≥ 10 
mg/daily or simvastatin ≥ 40 mg daily according to literature (19).  
The study was approved by our local Ethical Committee and informed consent was obtained by all 
patients. The study was conducted in accordance with the Declaration of Helsinki.  
Main demographic, clinical and angiographic data, together with the indication to dual antiplatelet 
therapy were recorded at discharge and included in a dedicated database, protected by password. 
Patients receiving concomitant vitamin D supplementation were excluded. As previously described 
(20) hypertension was defined as systolic pressure > 140 mm Hg and/or diastolic pressure > 90 mm 
Hg or if the individual was taking antihypertensive medications. Diabetes mellitus was defined as 
previous diagnosis, specific treatment administration (oral drug or insulin), fasting glycemia > 126 
mg/dL or HbA1c > 6.5%. Chronic renal failure was considered for a history of renal failure or an 
admission glomerular filtrate (GFR) < 60 mol/min/1.73m2 by MDRD (Modification of Diet in renal 
Disease) formula.  
 
 
Biochemical measurements  
Fasting blood samples were drawn from all patients for main chemistry and vitamin D levels 
assessment at baseline, at admission and at planned follow-up. Vitamin D dosing was performed by 
chemiluminescence method through LIAISON® Vitamin D assay (Diasorin Inc). The normal range for 
25-OH D3 levels in our laboratory is from 30 to 100 ng/ml, according to literature reference (21). 
Platelet function assessment  
Platelet aggregation was measured by a whole blood test, the impedance aggregometry (Multiplate®- 
multiple platelet function analyser; Roche Diagnostics AG) For Multiplate a whole blood sample was 
stored in Vacutainer standard lithium heparin tubes and analyzed within 1-2 hours from collection 
(22). Tests with different agonists were performed: arachidonic acid (AA), collagen, ADP and 
prostaglandin E1 and thrombin receptor activating peptide (TRAP-6). Results were expressed as 
arbitrary Aggregation Units (AU) and plotted against time, defining platelet function as the area under 
curve (AUC or AU*min).  
Statistical analysis                                       
Statistical analysis was performed using SPSS 17.0 statistical package. Continuous data were 
expressed as mean + SD and categorical data as percentage.  Patients were divided in 2 groups: in 
the “eq-S” group we included patients already receiving at admission a high-intensity statin, that was 
maintained on discharge, while the “Inc-S” were considered patients who started a high-intensity 
statin therapy or increased the dose or a previous treatment on discharge. Analysis of variance and 
the chi-square test were used for continuous and categorical variables, respectively. Linear regression 
analysis was performed to evaluate the relationship between changes in vitamin D levels and the 
reduction in low-density lipoprotein (LDL) cholesterol. The Mann-Withney U test was used to 
compare median follow-up values. The changes in vitamin D and LDL cholesterol levels were 
considered both as an absolute difference or as % variation, as compared to baseline.  A p value < 
0.05 was considered statistically significant.   
Table 1. Clinical characteristics according to statins therapy dosage. 
Baseline clinical characteristics 
Inc-Statin 
therapy 
 
N= 142 
eq-Statin  
therapy 
 
N= 104 
P value 
Age (mean±SD) 63.9±11.6 67.2±8.8 0.01 
Ag ≥75 years (%) 21.7 21.2 0.99 
Male Sex (%) 75.9 85 0.29 
BMI (mean±SD) 27.5±4.7 27.9±4.8 0.41 
Hypercholesterolemia(%) 57.4 69 0.05 
Diabetes mellitus (%) 39.5 52.2 0.03 
Renal failure (%) 12.7 16.8 0.40 
Active smokers (%) 36 14.2 <0.001 
Hypertension (%) 69.8 82.3 0.02 
History of MI (%) 13.3 34.5 <0.001 
Previous PCI (%) 26.5 62.8 <0.001 
Previous CABG (%) 7.9 13.3 0.16 
Indication to angiography   <0.001 
Stable angina/ silent ischemia (%) 21.6 54.9  
STEMI/ACS (%) 74.7 41.6  
Other (%) 3.7 3.5  
Severe left main/trivessel CAD (%) 24.7 41.1 0.005 
Hypovitaminosis D (%) 22.3 23.4 0.87 
Concomitant medications (at follow-up)    
ACE inhibitors(%) 59.5 48.7 0.07 
ARB (%) 17.4 29.2 0.02 
Beta blockers (%) 84.2 82.3 0.75 
Nitrates (%) 40 52.2 0.04 
Calcium antagonists (%) 16.8 32.7 0.002 
Diuretics (%) 21.6 32.7 0.04 
Ticagrelor(%) 78.9 56.7 0.06 
CAD = Coronary Artery Disease; MI = Myocardial Infarction; PCI = Percutaneous Coronary Interventions; CABG = 
Coronary Artery Bypass Grafting; STEMI = ST-Elevation Myocardial Infarction; ACS = Acute Coronary Syndrome; CMD 
=Dilated Cardiomyopathy; LV = Left Ventricle; ACE = Angiotensin Converting Enzyme; ARB = Angiotensin Receptor 
Blockers;  
Results 
Our population is represented by a total of 246 patients. Among them, 142 patients were discharged 
on a new statin therapy or with an increase in previous dose (Inc-S), while 104 were receiving at 
admission a high-intensity statin, that remained unchanged (eq-S). As shown in Figure 1, in the Inc-S 
group 69.8% of patients received atorvastatin and 30.2% rosuvastatin, while in the eq-S group, 52.9% 
of patients received atorvastatin, 43.3% rosuvastatin and 2.8% simvastatin. Median follow-up was 
75.5 days [Interquartile Range(IQR): 38-84.8]; not being different in the eq-S group (median: 65.5 
days; IQR[42-83]) or the Inc-S group (median 79 days; IQR[41-87], p value =0.19).  
Table 1 shows main demographic and clinical features of the study population. Patients in the Inc-S 
group were younger (p=0.01), smokers (p<0.001), with a lower history of hypercholesterolemia 
(p=0.05), diabetes (p=0.03), hypertension (p=0.02), or previous cardiovascular events (p<0.001). They 
were more often admitted for acute coronary syndrome (p<0.001) and used less frequently anti-
hypertensive drugs or nitrates. No difference in main chemistry parameters was observed, as 
displayed in Table 2, but for higher total circulating calcium in the Inc-S group (p=0.004). Also baseline 
vitamin D levels were similar in the 2 groups (p=0.30), while mean values of vitamin D at re-
assessment displayed a non significant trend for higher values in the Inc-S group (p=0.09).  
Figure 1 Distribution of statin therapy in study population (eq-S= statin dose unchanged, Inc-S= statin dose increased or 
new therapy started) 
 
 
 
 
 
 
 
 
Platelet reactivity was significantly lower in the Inc-S patients, when evaluating aggregation with 
different platelet activating stimuli (arachidonic acid, p=0.02, collagen, p=0.004, thrombin-activating 
peptide, p=0.07, ADP, p=0.002), Table 2. 
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Table 2. Biochemistry parameters at follow-up according to statin therapy dosage 
Biochemistry parameters α 
Inc-Statin 
therapy 
 
N= 142 
eq-Statin  
therapy 
 
N= 104 
P value 
Platelets (10^5/µl; mean± SD) 232.8±72.2 229.4±65.2 0.68 
Haemoglobin (g/dl± SD) 13.7±1.7 13.7±1,6 0.92 
WBC (10^3/µl;mean± SD) 8.5±6.6 7.9±1.9 0.45 
HDL cholesterol (mg/dL± SD) 41.3±12.2 40.9±11.2 0.76 
LDL cholesterol (mg/dl± SD) 69.8±24.1 70.5±25.7 0.82 
Triglycerides (mg/dl±SD) 121.5±80.5 133.2±66 0.20 
Fibrinogen (mg/dl± SD) 402±123.9 379.7±114.3 0.12 
Glycaemia (mg/dL± SD) 124.3±57.2 126.9±47.4 0.68 
Glycosylated haemoglobin (%± SD) 6.4±1.2 6.7±1.3 0.12 
Creatinine (mg/dL± SD) 0.9±0.5 1±0.4 0.32 
C reactive protein  (mg/dL±SD) 0.5±1.2 0.3±0.5 0.13 
Calcium (mg/dL±SD) 9.1±0.42 8.8±1.1 0.004 
Parathyroid hormone –active (mg/dL±SD) 65.9±47.5 69.1±49.5 0.61 
Vitamin D – follow-up (ng/ml±SD) 17.9±9.8 16.1±8 0.09 
Vitamin D – baseline (ng/ml±SD) 15.5±8.7 16.7±8.2 0.30 
ASPI test (AU*min± SD) 344±185.7 398.7±208.1 0.02 
COL test (AU*min± SD) 418.9±141.7 469.3±152.7 0.004 
TRAP test (AU*min± SD) 1070.2±266.8 1132.2±306.8 0.07 
ADP test (AU*min± SD) 307.6±172.1 374.3±181.9 0.002 
α mean values of each parameter are reported for dosing at follow-up but for baseline levels of vitamin D. 
A significant reduction in circulating low-density lipoprotein (LDL) cholesterol was observed in the 
Inc-S group, and not in the eq-S patients, when evaluating both absolute difference (-45.2±40.6 mg/dl 
vs -4.5±29.9 mg/dl, p<0.001) and the percentage of LDL reduction (-33.5±29.8 % vs -1.8±41%, 
p<0.001; Figure 2). Vitamin D levels increased in the Inc-S patients but not in the eq-S group (delta-
25OHD: 2.08±6.6 vs 0.26±7.5 ng/ml, p=0.048). Moreover, the variation was even enhanced among 
those 127 statin naive- patients at baseline, (delta vitamin D: 2.28±6.7).  
Results were similar when evaluating the percentage of 25OHD variation (23.2±20.5% vs 3.1±4.7%, 
p=0.003), as in Figure 3. 
 
 
 
Figure 2 Bar graph showing the difference in low-density lipoprotein (LDL) cholesterol, as delta LDL, after 30-90 days 
statin therapy in the 2 study groups (eq-S= statin dose unchanged, Inc-S= statin dose increased or new therapy started) 
 
 
 
 
 
 
 
 
 
Figure 3 Bar graph showing the difference in vitamin D levels, as delta 25-OH D, after 30-90 days statin therapy in the 2 
study groups (eq-S= statin dose unchanged, Inc-S= statin dose increased or new therapy started) 
 
We additionally observed a significant correlation between the lipid-lowering effectiveness of statins 
and vitamin D levels, as we described a linear relationship between the magnitude of vitamin D 
elevation and the reduction of LDL cholesterol (r=-0.17, p=0.01), Figure 4. 
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Figure 4 Linear regression between the magnitude of low-density lipoprotein (LDL) cholesterol decrease and the 
difference in vitamin D levels  
 
 
 
 
 
 
 
 
Discussion 
The present study represents one of the first and largest attempts to define the role of high-intensity 
statins on vitamin D levels and their impact on platelet function in patients with coronary artery 
disease (CAD).  
Our main finding is a significant elevation, when considering the variation from baseline, of circulating 
25-OHD after about 3 months of a new or increased dose- statin therapy, going along with a similar 
LDL-C reduction, that was not observed in a comparable group of patients chronically and stably 
treated with statins for coronary artery disease.  
Despite significant improvements in antithrombotic therapies and mechanical reperfusion strategies 
(23-25), the quote of patients experiencing acute cardiovascular events is still raising, thus requiring 
further efforts in developing measures for cardiovascular prevention (26).  
Therefore, particular attention has been focused to those non-canonical cardiovascular risk factors, 
such as hypovitaminosis D, that could offer innovative pharmacological targets and potential 
adjunctive benefits in patients with CAD (27). 
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Vitamin D deficiency, in fact, represents a worldwide health problem, whose social and economic 
impact is growing, together with the ageing of the population and the increasing complexity and 
frailty of patients treated for coronary artery disease.  
In fact, lower levels of 25-OHD have been inversely associated with vascular calcifications, arterial 
stiffness, major cardiovascular risk factors and with the extent of coronary artery disease (28,29). 
However, vitamin D has received, in the last few years, great interests also for its multiple effects on 
inflammatory system and atherothrombosis.  
In fact, its receptor has been identified also on inflammatory cells, where the active metabolites of 
vitamin D can inhibit leukocytes proliferation and the release of cytokines in the bloodstream (30), 
and even in platelets, preventing their aggregation (31).  
Similar anti-inflammatory, anti-oxidant and antithrombotic properties have been ascribed to statins, 
representing their non-lipid lowering related “pleiotropic effects (8).  
These non-lipid dependent benefits have emerged since the first large studies with statins, as the 
WOSCOP and CARE trials (32,33), where statin treated patients had a significantly lower 
cardiovascular risk as compared to non-statin treated patients with similar cholesterol levels.  
In fact, in addition to a reduction in the risk of major cardiovascular events of up to 21% for every 1 
mmol/l (39 mg/dl) decrease in LDL-C (34), statins have demonstrated to favour the improvement of 
endothelial dysfunction, increase nitric oxide bioavailability, inhibit inflammatory responses and 
promote a stabilization of atherosclerotic plaques (9). 
However, the underlying mechanism of statins’ “pleiotropic effects” is still poorly understood.  
Previous studies have suggested that these beneficial effects of statins could be dependent on an 
increase of vitamin D levels. In fact, Pérez-Castrillon et al. documented that vitamin D levels 
significantly increased in patients with acute ischemic heart disease after the treatment with 
atorvastatin (11). They postulated that the increase in 25-OH D induced by atorvastatin was a 
consequence of the inhibition of cholesterol synthesis at the HMG-CoA reductase enzyme, resulting 
in a raise in the levels of 7-dehydrocholesterol, a precursor of vitamin D. Analogous findings were 
observed with lovastatin and simvastatin in patients with familial hypercholesterolemia and with 
atorvastatin in patients with type 2 diabetes mellitus (17,35,36).  
In the Statin-D trial (37), 134 hyperlipidemic patients were randomized to fluvastatin or rosuvastatin 
therapy. After 8 weeks treatment, no change in 25-OH D was observed with fluvastatin, whereas 
rosuvastatin almost triplicated mean vitamin D levels and significantly decreased the activity of bone 
alkaline phosphatase. In fact, Staal et al. (38) demonstrated in cell culture experiments, that inhibition 
of osteoclastic activity was inversely correlated with the magnitude of a HMG-CoA reductase activity 
of statins, thus suggesting that higher-intensity statins could be more effective in modifying vitamin 
D levels.  
In contrast with these reports, however, Thabit et al. (39) identified no impact of simvastatin and 
atorvastatin, at any dose, for a duration of more than one year, on 25-OH D levels.  
Similar negative results were obtained by Anagnostis et al. in 63 dyslipidemic patients receiving 
atorvastatin or rosuvastatin for 12 weeks (40).  
Therefore, controversy still exists on the interaction of statin and vitamin D, with few data reported 
so far in subjects with proven CAD. Present study firstly included a population receiving high-intensity 
statins for secondary prevention after an acute coronary syndrome or PCI. We evaluated the 
modifications in vitamin D levels in patients with a first prescription of high-dose statin therapy or 
undergoing a dosage increase (Inc-S) versus those patients chronically and stably treated with statin 
(unchanged dosage at hospital discharge) (Eq-S).  
After 30 to 90 days treatment (median 75 days), vitamin D levels were unvaried in the Eq-S group 
while they significantly increased in the Inc-S group, with the extent of 25-OH D elevation depending 
on the magnitude of LDL-lowering effect. However, these acute effects, did not tend to progressively 
increase over time, as no difference in vitamin D levels was observed in patients chronically treated 
with statins.  
 In addition, the levels of platelet reactivity during dual antiplatelet therapy with ASA and clopidogrel 
or ticagrelor were significantly lower, with four different aggregating stimuli, in patients achieving a 
more significant increase in vitamin D levels.  
Indeed, the hypothesis of a crosstalk between vitamin D and statins metabolism had already been 
raised by Schwarz et al. (41), demonstrating that vitamin D supplementation could lower atorvastatin 
and its metabolites concentrations, while showing synergistic effects on cholesterol concentrations. 
In fact, CYP3A4 catabolizes vitamin D in liver and intestine (42). Statins are extensively metabolized 
and display an inhibitory activity on by CYP3A4 and CYP3A5. This common catabolic pathway may be 
responsible for the increased 25-OH D levels during statin treatment.  
In addition, Grimes (43) has suggested that statins might act as vitamin D analogues and compete 
with vitamin D for its receptor. Although rosuvastatin has not been clearly demonstrated to bind 
vitamin D receptor, it can target the glucocorticoid receptor and the thyroid beta-1 receptor, both of 
which interact with vitamin D metabolites.  
Therefore, the present data provide further confirmation and a more deep insight in explaining the 
beneficial role of statins- vitamin D interplay in patients at high cardiovascular risk, with a particular 
focus on platelet function.  
Nevertheless, the exact mechanism of such pharmacological interaction still needs to be elucidated 
in more dedicated studies, as far as a potential role of vitamin D supplementation in achieving the 
same cardio-protective effects with a lower dose of statins, improving tolerance and adherence to 
this drugs. In fact, higher 25-OH D levels have demonstrated to prevent statin-induced myalgia (44).  
 
Limitations.  
A first limitation is represented by the cross-sectional design of the study, including a certain degree 
of heterogeneity in patients’ characteristics and statin therapy. However, we deemed that this kind 
of population, including very high-risk patients, could be more representative of the real world 
population, therefore providing more helpful information for everyday clinical practice. Indeed, it 
might be argued that the clinical differences between the two study groups could have influenced 
the baseline levels of vitamin D. In fact, patients in the Eq-Statin therapy were significantly older, and 
with higher rates of diabetes, that are know risk factors for vitamin D deficiency. However, this 
observation further reinforces our hypothesis, as the chronic use of statins in these patients might 
potentially have counterbalanced their tendency to hypovitaminosis D. In fact, they displayed non-
inferior or even slightly higher baseline levels of Vitamin D, as compared to the Inc-Statin arm, even 
though not statistically significant.  
In addition, the sample size would not have allowed us to perform a subgroup analysis or a propensity 
score matching, that would have implied a further division of each group.  
Furthermore, the rate of patients on ASA+clopidogrel or ASA + ticagrelor was not different between 
the two groups, thus not having represented a potential confounding factor for our data on platelet 
reactivity. Indeed, the absence of a baseline assessment of platelet function  cannot allow to 
demonstrate the eventual changes in platelet reactivity induced by vitamin D raise, nevertheless, we 
previously demonstrated the strict relationship between Multiplate tests results and 25-OHD also in 
patients on DAPT (45). 
 Moreover, we did not evaluate whether vitamin D supplementation could improve the lipid-lowering 
effects of statins or the response to antiplatelet agents and we also excluded the few patients already 
on vitamin D therapy, as different dosing and formulations of the vitamin could have represented a 
potential bias.  
Finally, we did not collect data at long term follow-up, therefore we cannot tell on the impact of 
vitamin D levels or platelet reactivity on the occurrence of cardiovascular events in our patients. 
However, previous studies have already demonstrated the prognostic role of platelet reactivity, as 
defined by Multiplate aggregometry, on the risk of major ischemic events (46). 
 
Conclusion.   
In patients with coronary artery disease, the addition of a high-intensity statin treatment, besides the 
lipid-lowering effects, is associated to a significant increase in vitamin D levels and to lower platelet 
reactivity, potentially providing explanation of the “pleiotropic” benefits of statins therapy in 
cardiovascular disease.   
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Abstract 
Vitamin D deficiency has been implicated in the progression of atherosclerosis and acute thrombotic 
events. We aimed at evaluating the impact of vitamin D deficiency on periprocedural myocardial 
infarction (PMI) in patients undergoing percutaneous coronary interventions (PCI).  
We included 934 patients undergoing non-urgent PCI. Assessment of myocardial biomarkers was 
performed from 6 to 48 hours after PCI.  PMI was defined as Creatine Kinase-MB increase by 3 times 
the Upper Limit Normal or by 50% of an elevated baseline value, periprocedural myocardial damage 
as Troponin I increase by 3xULN or 50% of baseline.  
Patients were divided according to Vitamin D tertiles values (<10.2ng/ml; 10.2-18.7ng/ml; 
≥18.8ng/ml). Lower tertiles values of vitamin D were associated with age (p=0.04), female gender, 
(p=0.001), and a higher cardiovascular risk profile. Lower vitamin D levels related with PCI of 
descending anterior coronary artery or bypass vein grafts (p=0.03), treatment of bifurcations (p=0.05) 
and side branch loss (p=0.05) and inversely with direct stenting (p=0.002). However, lower Vitamin D 
levels did not influence the risk of PMI (adjusted OR [95%CI]=0.81[0.65,1.18],p=0.09) or 
periprocedural myocardial damage (adjusted OR[95%CI]=0.93[0.77,1.13],p=0.48). Similar results 
were achieved when considering the severity of vitamin D deficiency. 
Therefore, in patients undergoing PCI, no association was observed between vitamin D deficiency 
and the risk of periprocedural MI and myocardial damage. 
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Background 
Coronary artery disease is still the major determinant of mortality in developed countries, despite 
the great benefits in survival observed especially in the treatment of acute myocardial infarction [1,2]. 
Technological improvements and the introduction of innovative and more potent antithrombotic 
therapies have allowed an escalation in the complexity of percutaneous coronary interventions (PCI), 
therefore enhancing the risk of periprocedural complications [3].  
In fact, periprocedural myocardial infarction (PMI) can affect up to 30% of procedures, translating 
into negative outcome effects [4,5]. Principal detectable causes include coronary dissections, distal 
embolization or spasm, although myocardial damage can occur even in apparently uneventful 
procedures, due to the disruption or thrombotic obstruction of coronary microcirculation [6]. 
Elevated platelet reactivity and inflammatory response have been claimed as major determinant of 
these events, with parameters as C-reactive protein having been demonstrated to predict the 
occurrence of myocardial injury post-PCI [7].    
Great interests have been focused on Vitamin D (25OHD), for its multiple athero-protective and 
anti-inflammatory effects [8,9]. In fact, a long-term effect of vitamin D deficiency on the risk of 
cardiovascular disease is well established [10,11], while, few studies have so far addressed the role 
of vitamin D levels in patients undergoing PCI [12].  
Aim of current study was to assess the impact of vitamin D levels on periprocedural myocardial 
infarction (PMI) in patients undergoing coronary percutaneous revascularization.  
 
Methods 
Patients undergoing PCI at Ospedale “Maggiore della Carità” from January 2009 to January 2014 were 
prospectively included. Indication to PCI was both elective or acute coronary syndrome (UA/NSTEMI). 
NSTEMI patients were defined in case of chest pain at rest and cardiac biomarkers elevation >ULN 
(0,04 µg/l for Troponin I and 5,00 µg/l for CK-MB, respectively), with or without electrocardiographic 
changes, and were undergoing elective coronary angiography after pharmacological stabilization. 
STEMI patients and hemodynamically unstable patients or those requiring urgent angioplasty soon 
after admission were excluded, as much as those patients with baseline raising values of cardiac 
enzymes, not allowing the interpretation of PCI related variations. 
Diabetes mellitus was defined for previous diagnosis, use of specific hypoglycemic treatment (oral 
drug or insulin), fasting glycemia > 126 mg/dL in at least 2 repeated determinations or HbA1C > 6.5%. 
Hypertension was defined in case of systolic pressure > 140 mm Hg and/or a diastolic pressure >90 
mmHg or a chronic treatment with antihypertensive medications [13]. We considered a diagnosis of 
chronic renal failure for a pre-PCI glomerular filtrate (GFR) < 60 ml/min/1.73m2 by the MDRD formula 
(Modification of Diet in renal Disease) [14]. Patients treated with vitamin D supplementation at 
admission or with unavailable vitamin D status was were excluded. 
The study was approved by our local Ethical Committee, informed consent was obtained for the 
inclusion of the patients and the study was performed conform the declaration of Helsinki. According 
to guidelines, high-dose bolus of clopidogrel (600 mg) was administered to all patients at the time of 
hospitalization or before coronary angioplasty.  
Biochemical measurements   
Main chemistry parameters, including vitamin D, were assessed from fasting blood samples at 
admission [15]. and were determined by standard methods. All blood samples were processed within 
2 h from drawing. Cardiac biomarkers (Troponin I and CK MB) were dosed at baseline, before 
coronary revascularization, and at 6, 12, 24 and 48 h post PCI. 
Vitamin D levels were measured by chemiluminescence method through LIAISON® Vitamin D assay 
(Diasorin Inc). Normal laboratory range for 25OH D is from 30 to 100 ng/ml, vitamin D severe 
deficiency was considered for values < 10 ng/ml according to literature reference [16].  
Coronary angiography and PCI 
Coronary angiography was performed preferentially through a trans-radial approach by the Judkins 
technique, with 6-French catheters. Quantitative coronary angiography for the correct sizing of the 
lesions was performed by an automatic edge-detection system (Siemens Acom Quantcor QCA, 
Erlangen, Germany) [17]. Coronary angioplasty was performed by experienced operators with 
standard techniques. Indication to stenting, use of drug-eluting stents and implantation techniques, 
or the use of special techniques as rotational atherectomy, intravascular imaging or glycoprotein IIb-
IIIa inhibitors, was left at the decision of the operators. 
Study Endpoints  
Our primary endpoint was the occurrence of periprocedural MI, defined as CK-MB mass elevation > 
3 times the upper limit normal (ULN) or an increase by 50% of a baseline elevated value, if stable or 
falling at baseline. Secondary endpoint was myocardial damage, considered for a periprocedural raise 
of troponin I > 3 x ULN or by 50% of the pre-procedural value, if yet > 0.04 ng/ml.   
Statistical analysis  
SPSS 17.0 and 22.0 statistical package were used for statistical analysis. Continuous data were 
reported as mean + SD and categorical data in percentage. Analysis of variance and the chi-square 
test (or Fisher-test) were applied for continuous and categorical variables, respectively. Bonferroni 
correction was used for multiple comparison ANOVA. We conducted a multiple logistic regression 
analysis to evaluate the relationship between vitamin D levels and periprocedural myocardial necrosis 
or infarction after the inclusion in a “block” model of all the potential confounders (clinical and 
angiographic significant differences at univariate analysis). A propensity score was calculated by a 
forward conditional multivariable regression model and applied to perform a subgroup analysis 
assessing the impact of vitamin D on periprocedural MI according to the values of propensity score.  
Results 
Our population consists of 1132 patients undergoing PCI. Among them 46 (4.7%) received chronic 
therapy with vitamin D and were excluded from data analysis, as much as the 152 STEMI patients and 
patients undergoing urgent PCI, with a final population of 934 patients. Mean vitamin D levels in our 
population were 16.1±9.3 ng/ml.  
Table 1. Clinical characteristics according to Vitamin D tertiles. 
Baseline clinical characteristics 
I tert 
(<10.2 ng/ml) 
II tert 
(10.2-18.7 ng/ml) 
III tert 
(≥18.8 ng/ml) 
P value 
Age (mean±SD) 68.3±11.9 66.2±11.5 66.7±10.2 0.04 
Male Sex (%) 69.2 84.6 70.8 0.001 
BMI (mean±SD) 27±4.6 27.3±4.2 27.3±4 0.60 
Hypercholesterolemia(%) 64.7 62.1 57 0.05 
Diabetes mellitus (%) 41.5 38.5 37.8 0.34 
Renal failure (%) 22.3 15.7 15.5 0.03 
Family history of CAD (%) 30.5 35 30.9 0.92 
Smokers (%)    0.69 
Active smokers 28.2 26.6 18.9  
Previous smokers 22.3 25.6 28.3  
Arterial hypertension (%) 74.7 74.5 73.4 0.71 
History of MI (%) 30.2 25.1 24.2 0.09 
Previous PCI (%) 32.8 36.9 35.4 0.50 
Previous CABG (%) 16.6 12.7 12.4 0.14 
Autumn/winter admission 58.8 50.2 46.7 0.01 
Indication to angiography    <0.001 
Stable angina/ silent ischemia(%) 20.9 28.2 34.3  
ACS (%) 70.6 65.3 62.6  
Other (%) 8.5 6.5 3.1  
Therapy at admission      
ACE inhibitors(%) 40.7 40.5 34.4 0.1 
ARB (%) 18.7 20.6 21.1 0.46 
Beta blockers (%) 49.2 59.5 54.4 0.19 
Nitrates (%) 33.1 38.6 37.2 0.30 
Statins (%) 48.2 59.2 57.3 0.02 
Calcium antagonists (%) 19.3 18 21.4 0.52 
Diuretics (%) 32.1 24.5 18.3 <0.001 
ASA (%) 59.7 65.4 64.4 0.23 
Clopidogrel (%) 21 23.9 25.7 0.17 
Main chemistry     
Glycaemia (mg/dl) 129±61.8 128.8±58.8 124.9±41.4 0.56 
HbA1c (mmol/l) 46.7±15.6 46.2±15.3 43.6±10 0.01° 
Creatinine (mg/dL) 0.89±0.50 0.84±0.48 0.81±0.47 0.11 
Platelets (10^5/ml) 221±80.6 214.4±56.4 211.5±66.2 0.16 
Haemoglobin (g/dl) 12.7±1.8 13.1±1.7 13.2±1.6 0.002*,° 
WBC (10^3/ml) 7.8±2.8 7.3±2.5 7.3±2.5 0.01° 
Total cholesterol (mg/dl) 167.8±46.6 159±45.4 154.4±36.3 <0.001*,° 
LDL cholesterol (mg/dl) 97.7±38.5 92.2±42.9 87.8±33.4 0.006° 
Fibrinogen (mg/dl) 425.9±137.9 401.5±136.7 391.3±127.1 0.006° 
C reactive protein (mg/dl) 1.38±0.63 1.07±0.54 1.07±0.46 0.02 
Baseline Troponin I (ng/ml) 4.5±19.2 4.5±30.8 4.6±27.2 0.98 
Baseline CK-MB (µg/l) 27.7±68.4 22±58.2 24.2±58.6 0.67 
CAD = Coronary Artery Disease; MI = Myocardial Infarction; PCI = Percutaneous Coronary Interventions; CABG = 
Coronary Artery Bypass Grafting; STEMI = ST-Elevation Myocardial Infarction; ACS = Acute Coronary Syndrome; CMD 
=Dilated Cardiomyopathy; LV = Left Ventricle; EF = Ejection Fraction; ACE = Angiotensin Converting Enzyme; ARB = 
Angiotensin Receptor Blockers; ASA = Acetylsalicylic Acid; LDL = Low-Density Lipoproteins.  
 
* p<0.05 for I vs II tertile, †p<0.05 for II vs III tertile, ° p<0.05 for I vs III tertile 
Patients were divided according to vitamin D tertiles values (I tertile: <10.2 ng/ml; II tertile: 10.2-18.7 
ng/ml; III tertile: ≥ 18.8 ng/ml). Severe hypovitaminosis D (<10 ng/ml) was found in 302 patients 
(32.3%), whereas 47.9% of patients displayed values < 20 ng/ml. 
As expected, a seasonal variation in 25OHD was observed if the measurement of vitamin D was 
performed in autumn/winter (September to March) vs spring/summer (March to September) (mean 
value 14.9±8.9 vs 17.1±9.6 ng/ml, p<0.001, respectively), although largely remaining in the range of 
hypovitaminosis D (<30 ng/ml) for the majority of patients (93% vs 88.9%, p=0.03 for autumn/winter 
seasons vs spring/summer seasons, respectively).   
Table 1 displays main clinical and demographic features. Hypovitaminosis D was associated with age 
(p=0.04), female gender, (p=0.001), hypercholesterolemia (p=0.05), renal failure (p=0.03), acute 
coronary syndrome at presentation (p<0.001), treatment with diuretics (p<0.001), higher levels of 
white blood cells (p=0.01), HbA1c (p=0.01), fibrinogen (p=0.006), C- reactive protein (p=0.02), 
cholesterol (p<0.001) and lower haemoglobin values (p=0.002) and statins use (p=0.02).  
 
Table 2. Angioplasty Features according Vitamin D tertiles (per lesion). 
Procedural features 
 
I tert 
(<10.2) 
N= 394 
II tert 
(10.2-18.7) 
N= 396 
III tert 
(≥18.8) 
N= 394 
P value 
Severe CAD (% ) § 33.9 31.1 33.2 0.99 
Multivessel Disease (%) § 61.8 59.5 54.8 0.32 
Gp IIb-IIIa inhibitors (%)§ 49.4 51.9 46.4 0.52 
Clopidogrel bolus> 6 h 17.9 18.5 15.5 0.95 
Multivessel PCI (%)§ 27.9 29.6 26.5 0.72 
Lesion length (mm ± SD) 23.3±14 23.8±14.2 23.4±15.2 0.90 
Target Vessel  diameter 2.7±0.7 2.7±0.7 2.7±0.6 0.57 
 % stenosis (± SD) 88±9.9 89.5±9 88.9±9.7 0.22 
Target vessel    0.03 
Right Coronary Artery (%) 18.8 15.9 16.2  
Left Main (%) 2.8 4.3 2  
Left Anterior Descending 33 30.6 28.4  
Circumflex branch (%) 16.5 17.9 15  
Saphenous venous graft 3.8 3.3 2.5  
Antero-lateral branch (%) 12.7 16.7 12.9  
Eccentric plaque (%) 99.1 98 97.4 0.08 
Type C lesions (%) 32.8 34.8 34.4 0.64 
Calcifications (% ) 9.6 10 14.1 0.07 
Thrombus (% ) 9.9 8.8 7.5 0.30 
TIMI flow pre-PCI <3 (% ) 18.2 16.5 18.2 0.75 
Instent restenosis (% ) 5.5 6.9 8.5 0.13 
Chronical occlusion (% ) 7 6.3 8.6 0.45 
Bifurcations (% ) 29.9 30.9 22.7 0.05 
Predilatation(% ) 65.3 62.3 63.3 0.59 
Direct stenting ( %) 28.7 32.6 27.7 0.002 
BMS (%) 27.5 21.4 20.9 0.06 
Max inflation (atm± SD) 21.4±3.6 21.9±3.8 21.6±3.4 0.25 
Kissing balloon (% ) 16.7 23 22.1 0.11 
Thrombectomy ( %) 4.3 3 2.5 0.24 
Rotablator (% ) 1 0.7 1 0.8 
Drug-Eluting Stent  (% ) 74.2 79 80.2 0.11 
TIMI post PCI  <3 (%) 16.8 16.2 21.1 0.06 
Any dissection  (% ) 3.3 2.6 2.3 0.31 
Coronary perforation (% ) 2.1 0.6 1.7 0.63 
Distal embolization  (% ) 2.4 0.9 0.7 0.06 
Additional stent required  2.2 2.1 1.3 0.50 
Side branch loss (% ) 1.2 0.6 0 0.05 
§ per patient definition 
Table 2 lists main angiographic and procedural features (per lesion). Lower vitamin D levels related 
with PCI of lesions on descending anterior coronary artery or bypass conduct (p=0.03), treatment of 
bifurcations (p=0.05) and side branch loss (p=0.05) and inversely with direct stenting (p=0.002). No 
difference was found according to adjunctive pharmacological therapy during PCI.  
As displayed in Figure 1, Vitamin D levels did not influence the risk of PMI (15.7% vs 21.4% vs 20.9%, 
p=0.14, OR[95%CI]= 0.88 [0.64,1.17], p=0.08). No impact was found for periprocedural myocardial 
damage (62.8% vs 68% vs 66.4%, P=0.38, OR[95%CI]=0.90 [0.76,1.07], p=0.22) (Figure 2). 
Figure 1. Bar graphs show the prevalence (with standard error) of periprocedural myocardial infarction (defined as 
Creatine Kinase-MB by 3 times the Upper Limit Normal or by 50% of baseline value), according to vitamin D levels 
(tertiles).  
 
 
 
 
 
 
 
 
 
 
 
As shown in Table 3, the results did not change after correction for baseline differences.  In fact, no 
difference in the levels of vitamin D was identified in patients experiencing or not PMI (16±9 vs 
15.4±8.9 ng/ml, p=0.42) 
 
 
Figure 2. Bar graphs show the prevalence (with standard error) of periprocedural myocardial damage (defined as 
Troponin I  increase by 3 timed the Upper Limit Normal or by 50% of baseline value) according according to vitamin D 
levels (tertiles).  
 
 
 
 
 
 
 
 
 
 
Figure 3. Bar graphs show the prevalence (with standard error) of periprocedural myocardial infarction (A, upper graph) 
and myonecrosis (B, lower graph) according to vitamin D deficiency severity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similar results were obtained in the 317 patients with stable coronary artery disease (PMI:12.3% vs 
17.9% vs 13.5%, p=0.85; Myocardial damage: 71.3% vs 72.9% vs 71.7%, p=0.96) and among the 617 
ACS patients (PMI: 17.6% vs 24.6% vs 22.8%, p=0.16; Myocardial damage: 55.5% vs 62.4% vs 61.5%, 
p=0.27), that were confirmed after correction for baseline differences (Table 3).  
Results did not change when applying the cut-offs for the definition of the severity of vitamin D 
deficiency (<10 ng/ml- 10-30 ng/ml, > 30 ng/ml) (15.9% vs 21.1% vs 21%, p=0.14; for PMI and 62.8% 
vs 66.8% vs 69%, p=0.22, for myocardial damage; Figure 3) and at multivariate analysis (Table 3). 
Results were comparable also if considering patients with severe deficiency (<10 ng/ml) vs the rest 
of the population, as shown in Table 3.  
Table 3. Multivariate analysis results for the risk of periprocedural myocardial infarction and 
myonecrosis 
 
Variable Adjusted* OR CI P value P interaction 
Periprocedural myocardial infarction      
Vitamin D (across tertiles) 0.81 [0.65,1.18] 0.09  
Vitamin D  deficiency (severity) 0.69 [0.45;1.08] 0.11  
Vitamin D  deficiency (<  vs ≥ 10 ng/ml)   0.69 [0.847, 1.03] 0.07  
Stable coronary artery disease 0.96 [0.66, 1.41] 0.86 0.17 
Acute coronary syndromes 0.77 [0.59, 1.05] 0.08 
Periprocedural myocardial damage      
Vitamin D (across tertiles) 0.93  [0.77,1.13] 0.48  
Vitamin D  deficiency (severity)  0.87  [0.61-1.25] 0.47  
Vitamin D  deficiency (<  vs ≥ 10 ng/ml)  0.84 [0.63, 1.13] 0.25  
Stable coronary artery disease   0.92   [0.69, 1.23] 0.58 0.16 
Acute coronary syndromes 0.93 [0.71,1.21] 0.23 
 
* after correction for: age1, gender, hypercholesterolemia, renal failure, acute coronary syndrome, statins, diuretics, white 
blood cells1, HbA1c1, fibrinogen, C- reactive protein1, cholesterol, haemoglobin values and season of vitamin D dosing, 
treated segment, bifurcation lesion, side branch loss and direct stenting.    
 
In addition, similar results were achieved when comparing patients according to patients’ risk profile.  
A propensity score was calculated by multivariate regression analysis based on independent 
predictors of periprocedural myocardial infarction (previous MI: OR[95%%CI]= 0.46[0.27-0.77], 
p=0.003; therapy with angiotensin-receptor blockers: OR[95% CI]= 0.47[0.27-0.81], p=0.007; 
thrombus: OR[95%%CI]= 1.81[1.03-3.17], p=0.04; kissing balloon: OR[95%%CI]= 1.63[1.04-2.54], 
p=0.03; slow- flow: OR[95%%CI]= 6.2[2.6-14.73], p<0.001) . In fact, a similar rate of PMI was observed 
according to median values of propensity score (< or ≥0), for patients with severe vitamin D deficiency 
vs the rest of the population (low propensity score: 6.7% vs 11.7%, p=0.21; high propensity score: 
19.5% vs 24.4%, p=0.21, p interaction =0.09), Results did not change also for periprocedural 
myocardial damage (low propensity score: 64.8% vs 64.5%, p=0.17; high propensity score: 61.1% vs 
67.2%, p=0.99, p interaction = 0.28).  
Moreover, no difference was observed in the subgroup of patients treated with GPIIbIIIa inhibitors 
(n=422) in terms of periprocedural MI (16.4% vs 18.9% vs 21.7%, p=0.11) and troponin-myocardial 
damage (66.2% vs 66.9% vs 73.4%, p=0.38) and among patients not receiving periprocedural GPIIbIIIa 
inhibitors (13.2% vs 21.3% vs 13.2%, p=0.14 for PMI and 59.7% vs 66.7% vs 63.5%, p=0.49 for 
myocardial damage).  
 
Discussion 
Present study firstly addresses the impact of vitamin D levels on the occurrence periprocedural 
myocardial infarction. Our principal finding is that lower levels of 25OH D do not influence the risk of 
myocardial damage in patients undergoing PCI.  
Percutaneous coronary interventions (PCI) are nowadays the main revascularization strategy among 
patients with coronary artery disease. However, pharmacological and technical innovations [18,19] 
have not completely overcome the limitations of PCI in more complex patients, where still suboptimal 
results can be observed [20,21].  
In particular, procedural complications, as distal embolization, flow-limiting dissections or side branch 
loss are well established causes for the occurrence of periprocedural myocardial infarction (PMI), a 
feared event still occurring in several patients undergoing PCI and with an unfavorable impact on 
prognosis [22].  
However, a silent myocardial damage has been detected even apparently uncomplicated PCI, 
probably consequence of a coronary microvascular thrombosis [23], that can certainly be favored by 
elevated platelet reactivity and enhanced inflammatory status. However, very few data have been 
reported on the role biomarkers possibly predicting such complication [24].   
Great attention has been recently addressed to vitamin D, for its potential effects on cardiovascular 
disease [25] in addition to the endemic dimension of the problem of hypovitaminosis D, [26, 27]. In 
fact, previous studies reported serum levels of vitamin D being inversely associated with the extent 
of coronary disease [28] and with indirect markers of atherosclerosis, as coronary calcifications or 
carotid IMT [29]. Moreover, in the large Multi-Ethnic Study of Atherosclerosis (MESA), lower serum 
25OH D concentration increased the risk of cardiovascular events at 8 years follow-up among white 
race participants, where mean value of vitamin D was 10.6 ng/ml [30]. More recently, Naesgaard 
reported Vitamin D levels to predict mortality in females admitted for acute coronary syndrome, in a 
population where about 50% of the women displayed vitamin D deficiency [31]. Indeed, lower 
vitamin D levels have been linked to the pathogenesis of established cardiovascular risk factors, as 
hypertension [32] or hypercholesterolemia [33] and to the etiology of atherothrombosis, enhancing 
endothelial dysfunction and the inflammatory response [34,35], while contrasting data have been 
obtained for the long-term risk of diabetes [36]. In a previous study, Gupta et al. [37] reported that 
inadequate vitamin D levels could potentiate the risk of coronary restenosis after stent implantation 
in a swine model, by modulating neointimal and smooth muscle cells proliferation through 
atherogenic cytokines, including TNF-a. Similar results were suggested by Monraats et al in a model 
evaluating the genetic predictors of instent restenosis [12]. Moreover, vitamin D has been reported 
to inhibit the reactivity of platelets both in vitro and in vivo [34]. However, the role of vitamin D levels 
on periprocedural myocardial damage has never been assessed.  
We currently confirmed the significant prevalence of hypovitaminosis D among the white population, 
and especially among patients with CAD, as those included in our study. Moreover, we found a 
significant inverse relationship among 25OH D levels and ageing, female gender and renal function. 
Lower vitamin D levels were associated to significantly higher cholesterol and LDL levels, despite 
statins treatment, thus further pointing at a potential interaction of vitamin D with lipids metabolism, 
as previously suggested [38].  
Finally, we confirmed a significant association of hypovitaminosis D with acute coronary syndromes 
and with the elevation of inflammatory biomarkers [37]. 
However, vitamin D levels did not impact on periprocedural MI or myocardial damage, even after 
correction for baseline differences, and even when considering the definition of the severity of 
vitamin D deficiency. In addition, similar results were obtained in patients with either acute or elective 
presentation.  
Several explanations can be provided for our current negative result. Indeed, PMI recognizes a 
different pathogenesis from atherosclerosis and restenosis and probably coronary anatomy and 
lesion complexity had in our patients a more relevant impact on PMI. Adjunctive pharmacological 
therapies may have avoided a large quote of events in our patients, and in particular for statins, a 
category of drugs that are known to prevent myocardial damage during PCI and whose pleiotropic 
effects have been linked to a rise in the levels of vitamin D [38].  
In addition, the extensive use of GPIIbIIIa inhibitors in almost 50% of PCI may have helped to prevent 
the thrombotic phenomena, that are held responsible for PMI.  Finally, recent evidence has emerged 
on a paracrine, local-tissue production of the active vitamin D form, that could have offered a 
myocardial protection from periprocedural injury, independently from circulating levels of 25OHD, 
although this intriguing hypothesis still needs to be verified in large studies [39]. Nevertheless, despite 
the association of higher levels of vitamin D with a lower cardiovascular risk-profile, according to the 
present study, vitamin D supplementation should not be overlooked as a potential strategy for the 
prevention of periprocedural myocardial infarction among patients undergoing PCI.  
Study limitations 
A major limitation to our study is certainly represented by the absence of a long-term follow-up. 
Therefore we cannot excluded any potential prognostic effect of low vitamin D on the occurrence of 
thrombotic complications at distance.  In addition, the long period of patients recruitment, with 
seasonal variability of vitamin D levels could have slightly modified our results, although inadequate 
vitamin D levels were observed in the vast majority of our patients. On the other side, the high 
prevalence of hypovitaminosis D could have conditioned our negative observations. However, 
previous large studies (NHANES III, Framingham Offspring Study; [40-41]) have suggested that the 
increase in cardiovascular risk could be observed even for very low vitamin D levels (below 15 or 20 
ng/ml), that were reached in about 30% of patients in the study of Wang et al. and half of our study 
population. Therefore, we expect that we would have been able to detect any impact of vitamin D 
on PMI, if present. Nevertheless, the exact levels of 25OH D needed for cardiovascular protection are 
still matter of debate, and therefore we cannot exclude that a vitamin D supplementation in our 
patients undergoing PCI would have prevented a quote of periprocedural complications. Moreover, 
life-style and genetic factors could have influenced the levels and effectiveness of vitamin D. In fact, 
several polymorphic variants of vitamin D binding protein and vitamin D receptor can regulate the 
hormonal effects of 1,25OH2D and the pathways leading to activation and deactivation of vitamin D 
into its active hydroxylized metabolites. In fact, we excluded patients receiving chronic 
supplementation with vitamin D, but we did not collect data on sporadic treatments with 
multivitamins, that could have indeed influenced the levels of vitamin D in certain patients.  
The inclusion of patients with previous cardiovascular events, and especially those with a previous 
myocardial infarction or complex coronary anatomy, such as coronary artery bypass grafts, may have 
represented a population at higher risk of periprocedural myocardial injury, although these factors 
were equally distributed across vitamin D tertiles in our population. Moreover, patients with ST-
segment elevation myocardial infarction or persistent ischemia, requiring urgent revascularization, 
were not included and therefore we did not expect that time from symptoms onset to balloon 
inflation might have played a relevant role our study. In addition, we could not define the cause of 
PMI in the whole cohort of our patients, since evident periprocedural complications occurred only in 
a minor proportion of our patients, although not differing according to the levels of vitamin D. 
Furthermore, we could not apply the most recent definition of periprocedural myocardial infarction 
to our study, requiring the additional evaluation of symptoms, ECG and echocardiogram in addition 
to cardiac biomarkers, since these parameters were not required in the universal definition of PMI 
[42] that was in use at the beginning of the study and were therefore not available in the entire cohort 
of patients. Moreover, despite the 2007 Universal Definition defines Type 4a MI as either CK-MB or 
troponin elevation of >3× upper reference limit (URL), we preferred to use the CK-MB, over troponin. 
as a biomarker of PMI, being associated with the outcome for our primary study endpoint, as 
validated in principal studies on the topic. However, the “troponin” periprocerdural myocardial 
damage was also assessed, as a secondary study endpoint (5). 
 
Conclusions.  
In our study vitamin D deficiency was frequent among patients undergoing non-urgent PCI. However, 
we observed no association between vitamin D levels and the risk of periprocedural MI and 
myocardial damage.  
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ABSTRACT 
Background. 25-hydroxyvitamin D deficiency represents a widespread social problem but also an 
emerging risk factor for cardiovascular disease. Genetic variants of the Vitamin D Binding Protein 
(VDBP), the main transporter of vitamin D in the bloodstream, have been shown to account for a 
significant variability in the levels and systemic effects of vitamin D. We investigated whether the 
single nucleotide polymorphisms, rs7041 and rs4588, of VDBP are associated to the prevalence and 
extent of coronary artery disease.  
Methods A consecutive cohort of patients undergoing coronary angiography in a single centre were 
included. Significant CAD was defined as at least 1 stenosis > 50%, severe CAD for as left main and/or 
three-vessel disease. VDBP genetic status was assessed by polymerase chain reaction and restriction 
fragment length polymorphism technique. 
Results We included 1080 patients, 57% carried the mutated G allele of rs7041, whereas 22% carried 
the A allele of rs4588. Higher levels of C- reactive protein were observed in the carriers of G allele of 
rs7041 (p=0.02), whereas 25-hydroxyvitamin D levels were similar across groups. Higher prevalence 
of lesions in the left anterior descending artery and a longer lesion length were observed in “A” 
carriers for rs4588 (p=0.04 e p=0.03,  respectively). On the contrary, a higher prevalence of 
bifurcation lesions and chronic occlusions was observed in G carriers (p=0.002 and p=0.01 
respectively). Both polymorphisms of VDBP did not affect the prevalence of CAD (rs7041: 79.1% TT 
vs 80.3% TG vs 78.5% GG, p=0.81; rs4588= 80.3% CC vs 78.5% AC+AA, p=0.49) and severe CAD, 
(rs7041: 31.1% TT % vs 31.3% TG vs 30.6% GG, p=0.88; rs4588: 32.2% CC vs 29.3% AC+AA, p=0.31). 
Results were confirmed at multivariate analysis, for both rs7041 and rs4588. However, when 
including the levels of 25-hydroxyvitamin D to the multivariate model, we observed that 25(OH)D 
status and not genetic variants of VDBP were significantly associated to CAD (25-hydroxyvitamin D 
OR [95% CI] = 0.99 [0.97-1.0], p=0.05; rs7041 TG: OR [95% CI] = 1.26 [0.73-2.19], p=0.41; rs7041 GG: 
OR [95% CI] = 1.25 [0.82-1.91], p=0.30; rs4588 AC+AA: OR [95% CI] = 0.76 [0.51-1.13], p=0.18).  
Conclusion This study showed in a large cohort of patients undergoing coronary angiography, that 
the polymorphisms rs7041 and rs4588 of VDBP are not associated with the levels of 25-
hydroxyvitamin D nor with the prevalence and extent of CAD. In fact, 25-hydroxyvitamin D levels but 
not VDBP genetic status independently predicted the occurrence of coronary lesions at angiography. 
Keywords: Atherosclerosis; Vitamin D; VDBP; Polymorphisms 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
Recent advances in the fields of pharmacological treatment and percutaneous coronary 
revascularization have reduced overall mortality but not the burden of acute cardiovascular events, 
in patients with coronary artery disease (CAD) [1,2,3], and especially among higher-risk subsets of 
patients [4,5,6]. Therefore, in the last years, increasing efforts have been accomplished to identify 
correlates of coronary artery disease beyond well-known risk factors. Several markers of 
atherosclerosis have been proposed, although allowing only an early identification of cardiovascular 
disease, rather than its real prevention [7]. Thereby, a special attention has been paid to genetics, 
and especially to those common variants, the single nucleotide polymorphisms (SNP), potentially 
involved in the pathogenesis of atherosclerosis. 
Vitamin D is a group of fat-soluble molecules and plays role of steroid hormone, regulating calcium 
and phosphorus metabolism, but also playing a key function in cardiovascular health, improving 
endothelial function, decreasing inflammatory response with a consequential anti-atherogenic role. 
In fact, previous studies have identified hypovitaminosis D as an independent predictor of 
cardiovascular mortality and cardiovascular events in large cohorts of healthy subjects [13]. 
However, approximately 85%–90% of circulating 25(OH)D is tightly bound to vitamin D binding 
protein (VDBP), representing the body reserve of inactive vitamin D [8]. VDBP is an α2-glycosylated 
globuline [9], that presents three different allelic variants, defined as Gc1F, Gc1S and Gc2 [10]. These 
allelic variants depend on two SNPs, rs7041 and rs4588 locate in exon 11 of chromosome 4 [11]. Gc1F 
is the ancestry variant, more common in black and Asiatic populations, while Gc1S, consequent to a 
replacement T à G in rs7041, is frequent in white patients. Finally, Gc2, due to the missense 
mutation Cà A in rs4588, is mostly present in Caucasian people [12]. The latter have been previously 
linked to an elevation of VDBP levels and higher affinity for 25(OH)D, thus conditioning its 
bioavailability and effects and modulating the potential cardioprotective benefits of vitamin D 
supplementation. 
The aim of the current study was to investigate in a large consecutive cohort of patients undergoing 
coronary angiography the relationship between rs7041 and rs4588 of Vitamin D Binding Protein, the 
levels of vitamin D and the prevalence and extent of CAD. 
METHODS 
We included consecutive patients undergoing coronary angiography between January 2010 and 
January 2015 at the Azienda Ospedaliera-Universitaria, “Maggiore della Carità”, Novara, Italy. 
Informed consent was obtained from all patients before angiography. The protocol was approved by 
our local Ethical Committee and is in accordance to the Declaration of Helsinki statements. All 
demographic and clinical data were prospectively collected in a dedicated database. Hypertension 
was defined as a systolic blood pressure (BP) > 140 mmHg and/or a diastolic BP > 90 mmHg or on-
treatment with antihypertensive medications. The diagnosis of diabetes was based on previous 
history of diabetes treated with or without drugs, fasting glycaemia > 126 mg/dl or glycosylated 
haemoglobin > 6.5%. Hypercholesterolemia was defined as previous history of hypercholesterolemia, 
chronic treatment with any cholesterol-lowering agent at admission or fasting total cholesterol > 200 
mg/dl.  
Biochemical measurements 
Blood samples were drawn at admission from patients undergoing elective (following a fasting period 
of 12 h) or urgent coronary angiography for main chemistry and genetic assessment. Glucose, 
creatinine, uric acid levels, blood cells count and lipid profile were determined by standard methods, 
as previously described [14]. 25-hydroxyvitamin D measurement was performed by 
chemiluminescence method through LIAISON® Vitamin D assay (Diasorin Inc). The normal range for 
25-OH D3 levels in our laboratory is from 30 to 100 ng/ml, according to literature reference [15]. 25-
hydroxyvitamin D inadequate levels were considered for levels below 20 ng/ml, whereas deficiency 
for levels < 10 ng/ml according to the US Endocrine Society guideline [15]. 
VDBP polymorphisms genotyping 
Using a commercially available kit (GenElute™ Blood Genomic DNA, Sigma Aldrich) genomic 
deoxyribonucleic acid (DNA) was isolated from 200 ml of the peripheral blood samples. The rs7041 
and rs4588 polymorphisms were studied using combined polymerase chain reaction (PCR) and 
restriction fragment length polymorphism technique. Following PCR conditions were used: 1.5 µl of 
genomic DNA were amplified in a mix containing MgCl2 [3 mM], deoxy nucleotides (dNTPs) mix [3%], 
5% dimethyl sulfoxide (DMSO), 0.25 µl/100 ml DNA polymerase (GoTaq® Hot Start Polymerase, 
Promega) and a primers mix [3%], (where forward primer was: 5'-GAC TTC CAA TTC AGC AGC GA-3 ' 
and reverse: 5'-CCC TCC ACT TAA CAT GGC AG-3’), annealing temperature was settled at 60 °C. 
Figure 1. Electrophoresis on High Resolution agarose gel after restriction of Polymerase Chain Reaction product with the enzymes: 
HaeIII (Figure 1A), showing a double electrophoretic band for homozygotes GG patients or the three bands for TG heterozygotes for 
rs7041 and StyI (Figure 1B) showing a double electrophoretic band for AA patients or the three bands for AC heterozygotes of rs4588 
polymorphism. 
 
 
 
 
 
 
 
The polymorphism presence was evaluated by the pattern of length of restriction fragments after 
digesting PCR products by HaeIII (Thermo ScientificBsuRI) and StyI (Thermo Scientific Eco130I). 
In case of substitution between aspartic acid (T) and glutamine (G) in rs7041, HaeIII recognised a 
restriction site resulting in products of 271 and 132 base pairs, while in rs4588 the replacement 
between threonine (C) and lysine (A) generated a restriction site for StyI, resulting in two fragments 
of 278 and 125 base pairs. The digestion product was analysed with electrophoretic run on high 
resolution agarose 2.15% TAE gel (Figure 1 A and B). 
Coronary angiography                                                                                                        
Coronary angiography was routinely performed by the Judkins technique, preferring the radial 
approach, using 6-French right and left heart catheters. Quantitative coronary angiography was 
performed by two experienced interventional cardiologists [16] who had no knowledge of the 
patients' genetic data, by an automatic edge-detection system (Siemens Acom Quantcor QCA, 
Erlangen, Germany). After the visual inspection of the coronary artery, the frame of optimal clarity 
was selected, showing lesion at maximal narrowing and arterial silhouette in sharpest focus. After 
the calibration of guiding catheter, the analysed arterial segment with coronary lesion was defined 
by moving the cursor from the proximal to the distal part of coronary artery to ensure adequate 
determination of reference diameter. We have measured minimal luminal diameter, reference 
diameter, percent diameter stenosis and length of the lesion. 
Significant CAD was defined as at least 1 coronary stenosis > 50%. Severe multivessel disease was 
defined as three-vessel disease and/or left main disease. In case of patients who had previously 
undergone percutaneous coronary intervention, even though no restenosis was observed, the 
treated vessel was counted as significantly diseased. In previously bypassed patients, native arteries 
and grafts were taken into account in the evaluation of extension of artery disease (number of 
diseased vessels).  
Statistical analysis     
Statistical analysis was performed using SPSS 22.0 statistical package. Continuous data were 
expressed as mean + SD and categorical data as percentage. Analysis of variance and the chi-square 
test were used for continuous and categorical variables, respectively. The normality of the 
distribution was assessed by the Kolmogorov-Smirnov test. Patients were grouped according to 
genetic status of VDBP, performing a separate analysis for rs7041 and rs4588. For the latter SNP, 
carriers of the mutated allele either in heterozygosis and homozygosis were considered together. 
Multivariate logistic regression analysis was performed to evaluate the relationship between VDBP 
rs7041 polymorphism and rs4588 and coronary artery disease, after correction for baseline 
confounding factors that were entered in the model in block. Results were considered statistically 
significant for a two-tailed p < 0.05.   
 RESULTS 
We included in our study 1080 patients, among them 57% carried the mutated G allele of rs7041, 
355 (32.9%) in homozygosis whereas 433 (22%) carried the A allele of rs4588, with 43 (3.98%) 
homozygotes. The results were in line with the expected prevalence of the mutated alleles in 
Caucasian population and respected the Hardy-Weinberg equilibrium (p=0.15 for rs7041 and p=0.11 
for rs4588). 
Baseline characteristics according to the polymorphisms are shown in Table 1. 
No significant difference was observed in terms of main demographic and clinical characteristics 
according in carriers of the different allelic variants of VDBP, but for the observation of higher levels 
of C reactive protein for carriers of the G allele of rs7041 (p=0.02). 
Table 1 Demographic, clinical characteristics, therapy at admission and baseline chemistry for rs7041 
and rs4588 polymorphisms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MI = myocardial infarction, PCI= percutaneous coronary intervention; CABG=coronary artery bypass grafting, CVA= cerebrovascular 
accidents; LDL= low-density lipoproteins; HDL=high density lipoproteins, DCM = dilated cardiomiopathy. ASA= acetylsalicylic acid; 
ACE= angiotensin-converting enzyme; DCM = Dilated Cardiomyopathy; WBC = White Blood Cell; RBC = Red Blood Cell 
Table 2  Season values of Vitamin D according to genetic status of VDBP 
 
VDBP polymorphisms and vitamin D 
The prevalence of inadequate levels of vitamin D was 63.5% (686 patients), with 31.9% of patients 
displaying deficiency (< 10 ng/ml) of 25-hydroxyvitamin D. As shown in Figure 2, genetic status of 
VDBP did not affect the prevalence of hypovitaminosis D (rs7041: 38.6% TT vs 37.3% TG vs 34.7% GG, 
p=0.41; Figure 2.A; rs4588: 36.1% CC vs 37.6% AC+AA, p=0.70; Figure 2.B)  
Figure 2. Polymorphisms rs7041(A) and rs4588 (B) and prevalence of severe deficiency of 25-hydroxyvitamin D. 
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Variable Summer 
Mean ± SD 
p-value 
Winter 
Mean ± SD 
p-value 
p-value 
(intergroup) 
rs7041      <0.001 
TT 19.26 ± 11.3  13.8 ± 8.4   
TG 16.89 ± 9.9 0.19 13.6 ± 12.6 0.86  
GG 18.40 ± 11.1  14.1 ± 9.7   
rs4588     <0.001 
CC 17.9 ± 11.0 
0.88 
14.3 ± 9.6 
0.16 
 
AC+AA 17.7 ± 9.9 13.2 ± 7.7  
  
As expected, we found a significant seasonal variability between 25-hydroxyvitamin D level in winter 
and summer (17.8±10.8 vs 14.4±9.4; p<0.001). Nevertheless, these variations were not conditioned 
by genetic status (Table 2). 
VDBP polymorphisms and angiographic results   
Table 3 displays main angiographic findings (per lesion evaluation) according to VDBP genotypes. 
Higher prevalence of lesions in LAD and a longer lesion length were observed in rs4588 “A” carriers 
(p=0.04 e p=0.03 respectively). On the contrary, higher prevalence of bifurcation lesions and chronic 
occlusions were observed in “G” carriers (p=0.002 and p=0.01 respectively).  
However, neither rs7041 nor rs4588 polymorphisms did affect the prevalence of CAD  
(rs7041: 79.1% TT vs 80.3% TG vs 78.5% GG, p=0.81 - Figure 3. A; rs4588= 80.3% CC vs 78.5% AC+AA, 
p=0.49 - Figure 3. B).  
Figure 3. Polymorphisms rs7041 (A) and rs4588 (B) and prevalence of coronary artery disease (CAD). 
 
Similar data were observed when the prevalence of severe CAD (defined as left main and/or or 3-
vessel disease) was analyzed, for rs7041 (31.1% TT % vs 31.3% TG vs 30.6% GG, p=0.88) and for 
rs4588 (32.2% CC vs 29.3% AC+AA, p=0.31), as shown in Figure 4. A and 4. B. 
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Results were confirmed after adjustment for baseline confounding factors (level of C-reactive 
protein) for rs7041 in heterozygotes (adjusted OR [95% CI] = 1.04 [0.68-1.61], p=0.85) and 
homozygotes (adjusted OR GG [95% CI] = 1.13 [0.81-1.6], p=0.47); and for rs4588 (adjusted OR [95% 
CI] = 0.90 [0.66-1.21] p=0.49 for A allele carriers). 
Figure 4. Polymorphisms rs7041 (A) and rs4588 (B) and prevalence of severe CAD. 
 
No impact of VDBP genetics was found also for severe CAD at multivariate analysis for rs7041 (TG: 
OR [95% CI] = 1.06 [0.72-1.55], p=0.78; GG: OR [95% CI] =0.99 [0.74-1.33], p=0.96) and for rs4588 
(AC+AA: OR [95% CI] =0.87 [0.67-1.14], p=0.31). 
Besides, when including the levels of circulating 25-hydroxyvitamin D to the multivariate model, 
25(OH)D status, but not genetic polymorphisms of VDBP resulted statistically associated to CAD (25-
hydroxyvitamin D: OR [95% CI] = 0.99 [0.97-1.0], p=0.05; rs7041 TG: OR [95% CI] = 1.26 [0.73-2.19], 
p=0.41; rs7041 GG: OR [95% CI] = 1.25 [0.82-1.91], p=0.30; rs4588 AC+AA: OR [95% CI] = 0.76 [0.51-
1.13], p=0.18). No significant interaction in the prevalence of CAD was observed between the genetic 
status of VDBP and severe hypovitaminosis D (< 10 ng/ml) for both rs7041 (25-hydroxyvitamin D > 10 
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ng/ml: 76.4% vs 80.4% for TT vs G –allele carriers, p=0.36; 25-hydroxyvitamin D < 10 ng/ml: 86.2% vs 
80.2%, p=0.30 for TT vs G –allele carriers, p interaction =0.91) and rs4588 (25-hydroxyvitamin D >10 
ng/ml: 82.8% vs 75% for CC vs A-carriers, p=0.02, for 25-hydroxyvitamin D < 10 ng/ml: 78.6% vs 
85.2%, p=0.16 for CC vs A-carriers, p interaction=0.32). 
Table 3 Angiographic Characteristics according to rs7041 and rs4588 polymorphisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CAD = Coronary artery disease; LAD = Left descending coronary artery; CX = Circumflex coronary artery; RCA = Right 
coronary artery; TIMI = thrombolysis in myocardial infarction 
 
DISCUSSION 
This is one of the largest studies conducted so far to evaluate the relationship between VDBP 
polymorphisms and the prevalence and extent of CAD. The main finding is that these polymorphisms 
are not associated with the prevalence and extent of CAD. Coronary artery disease still represents 
the leading cause of mortality in developed countries [1] and large interests have been focused on 
the identification of new biomarkers [16,17,18], that may be associated with coronary 
atherosclerosis. Particular attention has been focused on single nucleotide polymorphisms (SNPs), 
common genetic variants occurring in more than 1% of the population, whose potential role in 
predicting the risk of CAD and myocardial infarction has recently been pointed out in large genomic-
wide association studies [19]. 
A raising attention, nevertheless, has been addressed to vitamin D deficiency, due to its high 
prevalence in the world, ranging from 13 to more than 50% of healthy subjects in western countries, 
according to different studies. In addition, vitamin D has been identified with a relevant implication 
in cardiovascular health [13,15,20]. In fact, 25-hydroxyvitamin D is a hormonal precursor modulating 
calcium and bone homeostasis, but also involved in the pathogenesis of CAD. 
The NHANES III study showed an increased occurrence of angina, myocardial infarction and heart 
failure in subjects with vitamin D levels < 20 ng/mL [21] and similar results have been achieved in 
more recent cohort studies documenting an association between vitamin D deficiency and 
angiographic definition of CAD [22] or platelet reactivity [23]. Nevertheless, contrasting data have 
been reported so far on the potential benefits of vitamin D supplementation on cardiovascular 
outcomes [24-26]. 
Indeed, previous reports have suggested that the variations in the response to the treatment with 
vitamin D could be dependent on the role of Vitamin D Binding Protein (VDBP), that is the major 
transporter of the vitamin in the bloodstream. Moreover, this protein also allows the megalin-
mediated renal re-uptake of the complex Vitamin D-VDBP in the tubules, [27] therefore conditioning 
the pool of vitamin D, the levels of the free active form and its biological effects [9, 28]. Previous 
studies [12] have documented how Gc1S and Gc2 variants are associated with higher levels of VDBP, 
and then with a larger pool of 25(OHO)D than for Gc1F variant.  In effect, common genetic variations 
of VDBP have been reported to account for more than 80% of the variability of the circulating protein 
and for 10% of 25-hydroxyvitamin D levels [12]. In particular, the single nucleotide polymorphisms 
rs7041 is dependent on a TàG substitution in exon 11, that is responsible for the substitution 
AspàGlu, and translates in the allelic variant Gc1S of the protein, associated with more elevated 
levels of VDBP and an increased affinity for vitamin D. A similar mutation is provided by rs4588, a 
CàA substitution falling at 12 base pairs distance from rs7041, responsible for the Gc2 allelic variant 
of VDBP, in linkage disequilibrium with the previous (D’=0.99). In the previous ARIC study [29], the 
carriers of the rs7041 substitution, genetically predisposed to low 25-hydroxyvitamin D levels, 
showed a slightly increased risk of stroke at a median follow-up of 20 years. However, in the same 
study 25-OH D levels < 17 ng/m and not the genetic status of VDBP were linked to the risk of CAD 
[30]. 
In contrast, Powe et al. showed that the T allele of rs7041 was associated to lower levels of VDBP 
both in black and white population, potentially increasing the quote of free bioactive 25-
hydroxyvitamin D and therefore conditioning its cardioprotective effects [12].  
Our study represents one of the largest cohort of patients in which we assessed the relationship 
between VDBP polymorphisms and the prevalence of CAD. We documented that these two 
polymorphisms are not associated either with 25-hydroxyvitamin D levels or with the prevalence and 
extent of CAD, and even the result was independent from major risk factors for atherosclerosis after 
multivariate adjustments. 
Indeed, our findings are in contrast with the previous reports of Stakisaitis et al. [29], demonstrating 
that VDBP polymorphism rs7041 increased the risk of CAD (OR= 1.45, p=0.02), while rs4588 reduced 
this risk (OR= 0.69; p=0.03). However, the sample examined in their study was far smaller (154 
patients with CAD and 306 controls), and then, conclusion could have been conditioned by 
insufficient statistical power. In fact, no impact of VDBP genetics on CAD was documented in the 
larger ARIC study, even though the definition of coronary atherosclerosis did not require the 
mandatory angiographic assessment in all patients.  
Analogous conclusion had also been reached in the IMPROVE [31] study, where the rs7041 and 
rs4588 conditioned only 25-hydroxyvitamin D levels and not markers of early atherosclerosis as the 
carotid intima-media thickness.   
However, in our study we found an association between the G allele of rs7041 and the levels of C-
reactive protein, that is considered a marker of the activation of those inflammatory processes, 
involved in the progression of atherosclerotic plaque [32]. Thus, it could be hypothesized that carriers 
of the “G” allele might display a faster or more aggressive development of CAD as compared to other 
genetic variants of VDBP. In fact, we also observed an association of these allelic variants with the 
complexity of angiographic findings, since the “G” allele of rs7041 related with the rate of lesions 
involving a bifurcation, whereas rs4588 was associated with lesions length.  
Indeed, VDBP has directly involved in the modulation of the immune processes, favouring the 
chemotaxis of neutrophils, the pro-oxidative metabolism of macrophages and controlling the 
activation of  T lymphocytes [32,33].  
Nevertheless, pathophysiological mechanisms of this potential interaction are yet to be determined 
and we cannot exclude that these associations can represent occasional findings rather than real 
clinical associations. Therefore, larger studies with a prospective follow-up should be helpful in order 
to clear out the role of rs7041 variants in the progression of CAD and provide potential therapeutic 
implications for the indications to 25-hydroxyvitamin D supplementation. In fact, the recent 
randomized study by Scragg et al. did not show any benefit with a monthly dose of vitamin D on 
cardiovascular events at an average 3-years follow-up, although different findings could have been 
achieved when applying different strategies of supplementation and if accounting for the genetic 
variants of the proteins involved in vitamin D homeostasis [34].   
Study limitations 
Limitations of the present study include those inherent to any prospective but observational study. 
In fact, the lower prevalence of the polymorphisms, in addition to the unbalance between the two 
populations, might have reduced the statistical power of our study. In addition, the prevalence of 
hypovitaminosis D in our population was high, as we enrolled patients with established or high 
suspect of cardiovascular disease and displaying several cardiovascular risk factors, such as age, 
diabetes or renal failure, that represent factors favoring vitamin D deficiency. Indeed, a case-control 
study would have overcome this limitation, however, we performed such patients’ recruitment on 
purpose. In fact, by including a prospective cohort of patients undergoing coronary angiography, we 
could overcome a bias due to a potential patient selection, when they are retrospectively identified. 
Moreover, as coronary angiography still represents the gold standard technique to evaluate the 
presence and extent of CAD, we could not include a healthy control group in our study. In fact, the 
absence of symptoms would not have excluded with certainty the absence of coronary 
atherosclerosis, especially among elderly and diabetic patients, that represented a large proportion 
of our real-life population.  
We did not collect follow-up data, especially in patients undergoing coronary angioplasty, and thus 
cannot exclude an impact of these polymorphisms of the progression of CAD, occurrence of acute MI 
and risk of adverse events after PCI. In fact, we observed an association of rs7041 with the levels of 
C reactive protein, that have been proposed as a marker of vascular wall damage, potentially 
conditioning the evolution of atherosclerotic plaque. 
A further limitation could be the absence of VDBP levels dosing, which did not make possible the 
evaluation of real free vitamin D, and also the paucity of patients receiving vitamin D 
supplementation, not allowing a separate analysis for this subgroup of patients. 
CONCLUSION 
This study showed in a large cohort of patients undergoing coronary angiography, that the 
polymorphisms rs7041 and rs4588 of VDBP are not associated with the levels of 25-hydroxyvitamin 
D nor with the prevalence and extent of CAD. In fact, 25-hydroxyvitamin D levels but not VDBP genetic 
status independently predicted the occurrence of coronary lesions at angiography. 
Thus, until the results of larger studies become available, these polymorphisms cannot be considered 
risk factors for coronary and carotid atherosclerosis.  
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Abstract  
Background. Vitamin D deficiency represents a major health problem in general population, especially 
for its association with cardiovascular disorders and thrombotic risk, even in patients on dual 
antiplatelet therapy (DAPT). Vitamin D Binding Protein (VDBP) is the main transporter of vitamin D in 
the bloodstream and genetic polymorphisms of this protein have been shown to account for a 
significant variability of vitamin D levels and its systemic effects. Contrasting data have linked the 
rs7041 T G substitution with cardiovascular disease. However, no study has so far addressed the role 
of rs7041 polymorphism on platelet reactivity in patients on DAPT, that was the aim of the present 
study. 
Methods. Patients treated with DAPT (ASA and clopidogrel or ticagrelor) for an ACS or elective PCI 
were scheduled for platelet function assessment at 30-90 days post-discharge. Platelet function was 
assessed by Multiplate® (Roche Diagnostics AG), and VDBP genetic status by polymerase chain 
reaction and restriction fragment length polymorphism technique. Fasting samples were obtained 
for main chemistry parameters and vitamin D levels assessment.  
Results. We included 400 patients, 187 (46.8%) receiving clopidogrel and 213 (53.2%) ticagrelor. The 
genetic polymorphism rs7041 (TàG) was observed in 318 patients, (79.5%), in 38.7% of them in 
homozygosis.  Main clinical and chemistry features did not significantly differ according to genetic 
status, but for a higher rate of ACE-inhibitors and beta-blockers use among the carriers of the G allele 
(p=0.04 and p=0.01, respectively).  
VDBP genetic status did not affect the rate of HRPR with ADP-antagonists (25.6% vs 24.6% vs 28.5%, 
p=0.59; adjusted OR[95%CI]= 0.94[0.52-1.7], p=0.83 for T/G patients; adjusted OR[95%CI]= 1.14[0.6-
2.2], p=0.67 for G homozygotes).  
However, the rate of HRPR with ADP-antagonists was influenced by severe hypovitaminosis D (< 10 
ng/ml) only in patients carrying the G allele, especially in homozygosis (T/T: 25.9% vs 26.1%, p=0.99; 
G carriers: 22.1% vs 35.3%, p=0.02, p interaction=0.019; adjusted OR[95%CI]=1.93[1.11-3.34],p=0.02 for 
G carriers). 
Conclusion. The present study shows that rs741 polymorphism of Vitamin D Binding Protein does not 
affect platelet reactivity or the rate of HRPR among patients receiving DAPT. However, the carriage 
of the G allele could condition the impact of hypovitaminosis D on the response to antiplatelet agents, 
increasing the occurrence of HRPR especially in homozygotes, thus suggesting a more significant role 
of vitamin D deficiency among these patients.  
Keywords: vitamin D binding protein, vitamin D, platelet aggregation, dual antiplatelet therapy; 
clopidogrel, ticagrelor, coronary artery disease 
 
 
 
 
 
 
 
 
Introduction  
Optimal antithrombotic therapy and platelet inhibition represents a crucial point in the management 
of acute coronary syndromes (ACS), especially in patients undergoing percutaneous coronary 
interventions (1-3). Nevertheless, inadequate effectiveness of dual antiplatelet therapy agents has 
been described (4), and mainly with ADP-antagonists rather that with ASA, occurring in up to 10-30% 
of patients and depending on the type of drug and baseline thrombotic profile of the patient (5,6). 
Previous studies have shown an association between high residual platelet reactivity (HRPR) on DAPT 
and an increased risk of recurrent ischemic events and stent thrombosis, therefore raising the 
importance of addressing those factors that may predict an impaired response to antiplatelet agents 
(7-9).   
Among clinical conditions enhancing platelet reactivity, large interests have been focused on vitamin 
D deficiency (10), that represents a widespread condition, often involving those more complex and 
frail patients that display per se an increased cardiovascular risk, especially after coronary 
interventions (11-14). Nevertheless, contrasting data have been reported so far on the potential 
benefits of vitamin D supplementation on cardiovascular endpoints, as the protective effects on 
atherosclerosis and thrombosis shown by vitamin D in molecular models have not been 
demonstrated so far in large clinical trials and meta-analysis (15-17).  
Vitamin D Binding Protein (VDBP) is the major transporter of vitamin D in the bloodstream, and 
genetic variants of VDBP have been demonstrated to account for the 10% of the variability of 
circulating levels of vitamin D (18), therefore potentially conditioning its bioavailability and 
antiplatelet effect. In particular the rs7041 polymorphism is a missense AspàGlu mutation, 
depending from a TàG substitution in position 416 of exon 11. The allelic variant with G, defined as 
isoform Gc1S of the protein, is more frequent in Caucasians (minor allele frequency about 44%), and 
has been associated with increased levels of VDBP and higher affinity for the vitamin, thus reducing 
the quote of “free” bioactive vitamin D (19). However, no study has so far addressed the impact of 
rs7041 polymorphism of VDBP on platelet reactivity among patients on DAPT, that was therefore the 
aim of present study.  
Methods  
We included patients admitted Division of Cardiology, “Maggiore della Carità” Hospital, Eastern 
Piedmont University in Novara, Italy, from October 2009 to April 2016 requiring dual antiplatelet 
therapy for acute coronary syndromes or after PCI for stable coronary artery disease. Invasive 
treatment with coronary angiography and eventual coronary stenting was not a required inclusion 
criterion. All patients receiving at discharge dual antiplatelet therapy with ASA (100 to 160 mg daily) 
and ADP-antagonists (clopidogrel 75 mg daily  or ticagrelor 90 mg b.i.d) were scheduled for chemistry 
and platelet function tests evaluation at 30-90 days from discharge. The study was approved by our 
local Ethical Committee and informed consent was obtained by all patients.  
Main demographic, clinical and angiographic data, together with the indication to dual antiplatelet 
therapy were recorded at discharge and included in a dedicated database, protected by password. 
As previously described (20), hypertension was defined as systolic pressure > 140 mm Hg and/or 
diastolic pressure > 90 mm Hg or if the individual was taking anti hypertensive medications. Diabetes 
mellitus was defined as previous diagnosis, specific treatment administration (oral drug or insulin), 
fasting glycemia > 126 mg/dL or HbA1c > 6.5%. Chronic renal failure was considered for history of 
renal failure or an admission glomerular filtrate (GFR) < 60 mol/min/1.73m2 by MDRD (Modification 
of Diet in renal Disease) formula. The study was performed conform the declaration of Helsinki. 
Biochemical measurements   
Fasting blood samples were drawn from all patients for main chemistry and vitamin D levels 
assessment. Vitamin D dosing was performed by chemiluminescence method through LIAISON® 
Vitamin D assay (Diasorin Inc). The normal range for 25-OH D3 levels in our laboratory is from 30 to 
100 ng/ml, according to literature reference (21). Severe vitamin D deficiency was considered for 
levels beyond 10 ng/ml according to literature.  
Platelet function assessment  
Platelet aggregation was measured by whole blood tests, including impedance aggregometry 
(Multiplate®- multiple platelet function analyser; Roche Diagnostics AG) For Multiplate a whole blood 
sample was stored in Vacutainer standard lithium heparin tubes and analyzed within 1-2 hours from 
collection (22). Tests with different agonists were performed: arachidonic acid (AA), collagen, ADP 
and prostaglandin E1 and thrombin receptor activating peptide (TRAP-6). Results were expressed as 
arbitrary Aggregation Units (AU) and plotted against time, defining platelet function as the area under 
curve (AUC or AU*min). HRPR was considered for AU*min values above lower limit normal for ASA 
(HAPR), [range: 862 - 1344] or after ADP stimulation [range: 417 - 1030], respectively (23-24). The 
test was repeated in patients with HRPR to confirm the findings. 
Genetic analysis 
Genomic DNA was obtained from 200 ml of whole blood through a dedicated kit (GenElute Blood 
Genomic DNA, Sigma Aldrich). Target region of VDBP gene was amplified by polymerase chain 
reaction (PCR) using following primers: 5'- GACTTCCAATTCAGCAGCGA-3' and 5'- 
CCCTCCACTTAACATGGCAG -3’. Genomic DNA (1.5 µl) was amplified in 23.5 µl of a mix composed by 
standard concentrations of reagents, including MgCl2 3mM and 5% dimethyl sulfoxide. A negative 
control containing no genomic DNA was added for every PCR reaction. PCR product of 403 base pairs 
was then digested by restriction enzyme HaeIII (Thermo Scientific BsuRI), producing two fragments  
of 271 and 132 bp respectively in presence of the TàG substitution of rs7041.  
Statistical analysis                                       
Statistical analysis was performed using SPSS 22.0 statistical package. Continuous data were 
expressed as mean + SD and categorical data as percentage. Analysis of variance and the chi-square 
test were used for continuous and categorical variables, respectively. Patients were grouped 
according to genetic status of VDBP. Multivariate logistic regression analysis was performed to 
evaluate the relationship between VDBP rs7041 polymorphism and HRPR, after correction for 
baseline differences that were entered in the model in block. A p value < 0.05 was considered 
statistically significant. Linear regression analysis was performed to assess the relationship between 
platelet reactivity and vitamin D levels according to VDBP genetic status. 
Table 1. Clinical characteristics according to Vitamin D Binding Protein rs 7041 status 
Baseline clinical characteristics 
T/T 
N= 82 
T/G 
N= 195 
GG 
N= 123 
P value 
Age (mean±SD) 67.9±9.8 67.6±11 66.7±11.7 0.71 
Male Sex (%) 74.4 73.3 79.7 0.32 
BMI (mean±SD) 26.9±4 26.7±4.5 27.5±4.2 0.30 
Hypercholesterolemia(%) 60.5 54.6 55.3 0.52 
Diabetes mellitus (%) 30.9 34.9 35.8 0.69 
Renal failure (%) 18.3 17.6 17.1 0.82 
Active smokers (%) 23.2 22.6 30.1 0.27 
Hypertension (%) 71.6 69.1 75.6 0.44 
History of MI (%) 17.3 21.6 22 0.46 
Previous PCI (%) 29.6 25.1 28.5 0.95 
Previous CABG (%) 11.1 12.3 6.5 0.22 
Indication to angiography    0.12 
Stable angina/ silent ischemia (%) 26.8 25.1 31.7  
STEMI/ACS (%) 61 68.7 65  
Other (%) 12.2 6.2 3.3  
Concomitant medications     
ACE inhibitors(%) 37.8 52.3 53.7 0.04 
ARB (%) 26.8 18.5 22.8 0.63 
Beta blockers (%) 64.6 75.9 80.5 0.01 
Nitrates (%) 43.9 39.5 44.7 0.80 
Statins (%) 70.7 79.5 80.5 0.13 
Calcium antagonists (%) 18.3 20 22.8 0.42 
Diuretics (%) 39 26.7 30.9 0.32 
CAD = Coronary Artery Disease; MI = Myocardial Infarction; PCI = Percutaneous Coronary Interventions; CABG = Coronary Artery 
Bypass Grafting; STEMI = ST-Elevation Myocardial Infarction; ACS = Acute Coronary Syndrome; CMD =Dilated Cardiomyopathy; LV = 
Left Ventricle; ACE = Angiotensin Converting Enzyme; ARB = Angiotensin Receptor Blockers;  
Results 
Our population in represented by 400 patients, receiving DAPT (ASA/Clopidogrel in 187 patients 
(46.8%) and ASA/Ticagrelor in 213 patients (53.2%). Among them, 13 patients were receiving vitamin 
D supplementation. The genetic polymorphism rs7041 (T G) was observed in 318 patients, (79.5%), 
in 38.7% of them in homozygosis.  
As shown in Table 1 patients did not differ significantly for main clinical and demographic features 
according to genetic status, but for a higher rate of ACE-inhibitors and beta-blockers use among the 
carriers of the G allele (p=0.04 and p=0.01, respectively).  
VBDP polymorphism did not influence main chemistry parameters, including vitamin D levels and 
mean platelet reactivity, as displayed in Table 2.  
Table 2. Biochemistry parameters according to Vitamin D Binding Protein rs 7041 status 
Biochemistry parameters T/T T/G GG P value 
Platelets (10^6/ml; mean± SD) 241.1±78.4 235.4±66.6 228.2±66.8 0.41 
Haemoglobin (g/dl) 13.6±1.8 13.3±1.6 13.3±1.7 0.21 
WBC (10^3/ml;mean± SD) 7.9±2.2 7.9±3 8±2.2 0.99 
HDL cholesterol (mg/dL) 43.6±13.4 42.5±15.9 44.3±16.2 0.61 
LDL cholesterol (mg/dl) 80.9±35.9 77.4±29.2 76.3±32.7 0.58 
Glycaemia (mg/dL) 124.1±34 121.4±50.1 119.3±35.6 0.73 
Glycosylated hemoglobin (%) 6.4±1.2 6.2±1.1 6.4±1.3 0.18 
Creatinine (mg/dL) 0.98±0.33 1.04±0.72 1.04±0.59 0.71 
C reactive protein (mg/dL) 0.59±1.07 0.65±1.04 0.83±2 0.44 
Vitamin D (ng/ml) 17.2±9.6 17.4±9.9 18±11.6 0.84 
ASPI test (AU*min) 328.6±189 340.9±187.2 362.5±230.3 0.46 
COL test (AU*min) 471.6±151 461.1±147.6 470.8±166.3 0.81 
TRAP test (AU*min) 1217±349 1120.2±317 1116.9±342 0.47 
ADP test (AU*min) 345.8±199.4 322.2±178.6 347.2±180.3 0.41 
 
No difference was observed in the rate of HRPR with ASA (HAPR), as displayed in Figure 1 (2.4% vs 
1.5% vs 4.1%, p=0.37).  
VDBP genetic status did not also affect the rate of HRPR with the ADP-antagonists clopidogrel and 
ticagrelor (25.6% vs 24.6% vs 28.5%, p=0.59); Figure 2. Results were confirmed at multivariate 
analysis after correction for baseline differences (adjusted OR[95%CI]= 0.94[0.52-1.7], p=0.83 for T/G 
patients; adjusted OR[95%CI]= 1.14[0.6-2.2], p=0.67 for G homozygotes). 
Similar findings were observed in clopidogrel treated patients (34.8% vs 40.2% vs 40.7%, p=0.56) and 
with ticagrelor (13.9% vs 12.4% vs 17.2%, p=0.55) and when excluding the patients receiving vitamin 
D supplementation (24.1% vs 24.6% vs 28.9%, p=0.40). 
Patients with severe hypovitaminosis D (<10 ng/ml) displayed a significantly higher degree of HRPR 
with ADP antagonists (33.9% vs 22.3%, p=0.02).   
However, a significant interaction was observed between VDBP polymorphism and vitamin D levels, 
affecting platelet reactivity. In fact, as shown in Figure 3, the rate of HRPR with ADP-antagonists was 
influenced by hypovitaminosis D (< 10 ng/ml; n=108 patients, 27%) only among patients carrying the 
G allele, (T/T: 25.9% vs 26.1%, p=0.99; G carriers: 22.1% vs 35.3%, p=0.02; p interaction =0.019); and 
especially in homozygotes (respectively T/G: 21.4% vs 30%, p=0.25; G/G: 23.3% vs 42.9%, p=0.05).   
The increased rate of HRPR with ADP-antagonists in patients with hypovitaminosis D and G allele of 
rs7041 polymorphism was confirmed at multivariate analysis (T/T patients: adjusted 
OR[95%CI]=1.01[0.33-3.05], p=0.99; G carriers: adjusted OR[95%CI]=1.93[1.11-3.34]; p=0.02 for 
severe vitamin D deficiency).   
Similar results were obtained at linear regression analysis, when considering values of vitamin D as a 
continuous variable (T/T: r=0.12, p=0.29 and G carriers: r=-0.18, p=0.001), as shown in Figure 4 A and 
B respectively. 
 
 
 
Figure 1 Bar graph shows the prevalence of high-residual on treatment platelet reactivity (HRPR) for Acetylsalicylic acid 
(ASA) according to vitamin D Binding protein rs7041 genetic status.  
 
Figure 2 Bar graph shows the prevalence of high-residual on treatment platelet reactivity (HRPR) at ADP test 
according to vitamin D Binding protein rs7041 genetic status 
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Figure 3 Bar graphs show the prevalence of high-residual on treatment platelet reactivity (HRPR) at ADP test according 
to vitamin D levels (below or equal/above 10 ng/ml) and vitamin D Binding protein rs7041 genetic status 
 
Figure 4 Linear regression analysis of platelet ADP-mediated aggregation and vitamin D levels according to vitamin D 
Binding protein rs7041 genetic status. 
 
No interaction (p =0.49) was observed between clopidogrel and ticagrelor in the rate of HRPR with 
hypovitaminosis D and G allele (G carriers: 40.7% vs 37.7%, p = 0.80, in clopidogrel treated patients; 
16.7% vs 10.5%, p=0.48, in ticagrelor treated patients). 
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Discussion 
The present study represents the first attempt to define the role of rs7041 polymorphism of Vitamin 
D Binding protein (VDBP) on platelet aggregation in vivo, in patients receiving dual antiplatelet 
therapy for a recent ACS or PCI.  
Our main finding is the lack of an overall effect of this genetic variant on platelet reactivity or the 
effectiveness of antiplatelet agents. However, we observed a significant interaction between vitamin 
D levels and this polymorphism, as vitamin D deficiency was associated with a suboptimal platelet 
inhibition in response to ADP-antagonists only in the carriers of the G allele, especially in 
homozygosis.  
Even though a unique consensus on the definition and evaluation of high-on treatment platelet 
reactivity (HRPR) is still lacking, the achievement of an adequate level of platelet inhibition is 
universally accepted as a key point in the management of patients with acute cardiovascular events, 
especially in case of stent implantation (24-26).  
In fact, conditions enhancing platelet reactivity have been associated with an up to nine-times 
increased risk of recurrent ischemic events or stent thrombosis, although the underlying mechanisms 
have been poorly defined so far (27-29).  
Clinical conditions as far as genetics (30-31), have been involved in the suboptimal effectiveness of 
clopidogrel, with genetic polymorphisms of the cytochrome P450 accounting for a reduced 
transformation of the drug into its active form and therefore a lower platelet inhibition. However, 
HRPR has been reported in about 10% of patients even with more recently developed antiplatelet 
drugs as Ticagrelor or Prasugrel (6, 32), that are not depending on a complex hepatic activation as 
clopidogrel to display their effect, thus suggesting the existence of other mechanisms conditioning 
platelets activity and thrombotic risk.  
Vitamin D has received great attention as a hormonal factor modulating cardiovascular function, as 
its hydroxylated, active form (1,25-OHD) has been shown to prevent endothelial dysfunction and 
inflammatory processes (33-34), that represent the pathophysiological basis of atherosclerosis. In 
fact, vitamin D deficiency has been associated with a higher mortality and an enhanced cardiovascular 
risk in large scale registries, as in the Multi-Ethnic Study of Atherosclerosis (MESA) (35) and the 
National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 (36). 
However, the interest for the role of vitamin D on thrombotic risk has become even more relevant 
after the identification of vitamin D receptor (VDR) on platelets surface (37), where studies in vitro 
and in vivo have suggested that the vitamin D-VDR system could inhibit platelet reactivity (38-39). In 
fact, we previously documented in a cohort of 503 patients on DAPT that lower vitamin D levels were 
associated with higher platelet reactivity and impaired effectiveness of the ADP-antagonists 
Clopidogrel and Ticagrelor (40).  
Nevertheless, no study has so far evaluated the impact of vitamin D supplementation on platelet 
reactivity and contrasting data have been reported on its potential benefits on cardiovascular 
outcomes (15-17).   
Indeed, previous reports have suggested that the variations in the response to the treatment with 
vitamin D could be dependent on the role of Vitamin D Binding Protein (VDBP), that is the major 
transporter of the vitamin in the bloodstream, therefore conditioning the pool of vitamin D, the levels 
of the free active form and its biological effects (41-42).  
In fact, in a previous study, Lopez-Farrè et al. (43) reported higher vitamin D binding protein (DBP) 
levels in ASA resistant subjects and moreover, the addition of VDBP to whole blood of healthy donors 
significantly reduced the inhibitory effect of aspirin on TxA2 production, thus potentially suggesting 
that this protein could prevent the binding of vitamin D to its receptor and its antithrombotic effects. 
Moreover, common genetic variations of VDBP have been reported to account for more than 80% of 
the variability of the circulating protein and for 10% of vitamin D levels (19). In particular, the single 
nucleotide polymorphism rs7041, dependent on a TàG substitution in exon 11, is responsible for 
the substitution Aspà Glu, that translates in the allelic variant Gc1S of the protein, associated with 
more elevated levels of VDBP and an increased affinity for vitamin D.  
In the previous ARIC study (44), carriers of the rs7041 substitution, genetically predisposed to low 
vitamin D levels, showed a slightly increased risk of stroke at a median follow-up of 20 years.  
A similar impact of the G allele was documented among more than 500 Lithuanian patients 
undergoing coronary angiography (45), where the G allele increased the risk of CAD with an odds 
ratio (OR) equal to 1.45 (p< 0.02). In addition, G carriers displayed an increased cardiovascular risk 
profile according Mateos-Muñoz et al. (46), where this variant was associated with insulin resistance 
and in the study by Almesri et al. (47), showing an association of G allele with BMI. On the contrary, 
an opposite association of the T allele with the risk of incident diabetes was observed by Reis et al. 
(48) among Caucasians in another large scale registry.   
However, no study has so far addressed the role of this genetic variant of VDBP on platelet reactivity, 
and especially among patients on DAPT, that was the aim of the present study. We showed that the 
genetic status of rs7041 polymorphism of VDBP did not affect platelet reactivity or the occurrence of 
HRPR on antiplatelet treatment among 400 patients on maintenance DAPT after a recent acute 
coronary syndrome or elective PCI.  
In addition, this polymorphism did not affect vitamin D levels. Nevertheless, we observed a significant 
interaction between severe vitamin D deficiency and the G allele carriage for rs7041 of VDBP, 
conditioning  more enhanced platelet reactivity and a higher prevalence of poor responders to 
Clopidogrel/Ticagrelor and especially in homozygotes, suggesting that hypovitaminosis D and its 
correction could play a more relevant role among these patients, where the reduced bioavailability 
of vitamin D induced by its sequestration with VDBP complexes could render even more remarkable 
the impact of its deficiency.  
Therefore, future studies should be drawn to evaluate whether vitamin D supplementation can 
positively revert platelet hyperreactivity among the carriers of the G allele. In fact, vitamin D 
supplementation does not affect the genetically determined levels of VDBP, thus suggesting that the 
administration of exogenous vitamin D could directly impact on its free and biologically active quote 
(49). 
Limitations  
A first limitation can be considered the prospective design of the study, including a consecutive 
cohort of patients, thus leading to a certain unbalance between the different genetic status of the 
patients, with almost 80% of the patients carrying the G allele. However, this drawing was made on 
purpose, allowing to evaluate the weight of genetics in a real-life all-comers population, and to 
consider separately the homozygotes and heterozygotes for the G allele of VDBP. Moreover, the 
additive effect of hypovitaminosis D in G/G patients as compared to G/T ones further confirms our 
data. In addition, we did not collect data at long term follow-up, therefore we could not evaluate 
whether higher platelet reactivity related to the occurrence of cardiovascular events in our 
population. However, previous studies have documented the prognostic role of HRPR, as defined by 
Multiplate aggregometry, on the risk of major cardiovascular events (50-51).  
In addition, we did not measure the levels of circulating VDBP, and therefore we could not define the 
impact of this genetic variant on the total pool of vitamin D-VDBP in our patients. Nevertheless, the 
role of rs7041 in modulating the levels of VDBP is well established (19) and the identification of a 
differential effect of hypovitaminosis D on platelet reactivity according to the genetic status certainly 
support such findings.  
 
Conclusions  
The present study shows that rs741 polymorphism of Vitamin D Binding Protein does not affect 
platelet reactivity or the rate of HRPR among patients receiving DAPT. However, the carriage of the 
G allele can condition the impact of hypovitaminosis D on the response to antiplatelet agents, 
increasing the occurrence of HRPR especially in homozygotes, thus suggesting a more significant role 
of vitamin D deficiency among these patients.  
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ABSTRACT 
 
Background. Vitamin D deficiency represents an emerging risk factor for coronary artery disease and 
cardiovascular outcomes. Recent attention has been focused on the regulation of vitamin D 
metabolism and homeostasis as modulating the cardiovascular benefits of vitamin D. In particular, 
the functional impact of the genetic polymorphism rs2762939 of CYP24A1, the hydroxylase-enzyme 
modulating the inactivation of vitamin D, is still debated. Aim of the present study was to evaluate 
the relationship between rs2762939 genotype and the prevalence and extent of coronary artery 
disease in a large cohort of patients undergoing coronary angiography.  
Methods A consecutive cohort of patients undergoing coronary angiography in a single centre were 
included. Significant CAD was defined as at least 1 stenosis > 50%, severe CAD for as left main and/or 
three-vessel disease. CYP24A1 genetic status was assessed by polymerase chain reaction and 
restriction fragment length polymorphism technique. 
Results We included in our study 1024 patients, 673 carried the C allele, (wild-type G: 66%; C-allele 
34%; Hardy-Weinberg p=0.15). Baseline clinical and demographic features were well balanced 
between the two groups, but for a lower use of beta-blockers among the C-carriers (p=0.01) and 
higher levels of C-reactive protein (p=0.05). 30.9% of the patients displayed hypovitaminosis D and 
2.1% of patients received vitamin D supplementation, with no difference according to genotype. The 
prevalence of CAD and severe CAD was not conditioned by CYP24A1 genetic status (78.7% GG vs 
81.2% C-carriers; p=0.31; adjusted OR  [95% CI]= 0.71 [0.20-2.56], p=0.60 and 29.1% GG vs 29.5% C 
carriers p=0.95; adjusted OR [95% CI]= 0.87 [0.73-1.04], p=0.13, respectively). However, the 
prevalence of coronary calcifications was significantly higher among GG homozygotes (p=0.005). 
 
Conclusion This study showed in a large cohort of patients undergoing coronary angiography, that 
the polymorphisms rs2762939 of CYP24A1 is not associated with the prevalence and extent of CAD. 
However, the C-allele mutation carriage significantly lowers the rate of coronary calcifications. 
Keywords: Atherosclerosis; Vitamin D; VDBP; Polymorphisms 
 
 
INTRODUCTION  
Recent developments in the field of pharmacological therapy and in the strategies for coronary 
revascularization have significantly improved the prognosis of patients with coronary artery disease 
(CAD) (1-3). However, ischemic heart disease still represents the leading cause of mortality 
worldwide, and preventive measures for contrasting the progression of atherosclerotic disease still 
fail for a large part in reducing the burden of CAD (4). Several studies have been conducted so far, 
aiming at the identification of new predictors and early markers of cardiovascular risk (5-7). 
Over 10-years of genome-wide association studies have addressed several genetic variants 
potentially linked to the pathogenesis of CAD, with contrasting results (8).  
Vitamin D deficiency, a common condition affecting over half of the general population, has also 
recently emerged as a major determinant of cardiovascular events and impaired long-term outcomes 
(9,10). Therefore, the loss of the anti-inflammatory, anti-thrombotic and cardioprotective effects of 
vitamin D has been pointed as a new potential target for cardiovascular prevention, although not 
providing, so far, the expected benefits (11). Dysregulation in the metabolism of vitamin D and in its 
transformation into the hydroxylated, biologically active, isoform (calcitrol or 1,25(OH)2D) have been 
suggested as potential determinants of this variability of the results (12). In particular, a reduced 
activity of the CYP24A1 enzyme, responsible for the inactivation of calcitriol, has been associated to 
its accumulation and nephrocalcinosis (13), whereas an opposite increase has been linked to 
insufficient effect of vitamin D and cancerogenesis(14). The single nucleotide polymorphism (SNP) 
rs2762939 of CYP24A1 is dependent from a CàG substitution in intronic position, with a minor allele 
frequency of 29% in Caucasic population (15), potentially conditioning the protein expression and the 
activity of CYP24A1. Despite initial promising data linking this variant with the pathogenesis of 
coronary atherosclerosis, no study has so far directly addressed its role on the prevalence and extent 
of angiographically defined CAD, that was therefore the aim of the present study.  
METHODS 
 
We included consecutive patients undergoing coronary angiography between October 2012 and June 
2016 at the Azienda Ospedaliera-Universitaria, “Maggiore della Carità”, Novara, Italy. Informed 
consent was obtained from all patients before angiography. The protocol was approved by our local 
Ethical Committee and is in accordance to the Declaration of Helsinki statements. All demographic 
and clinical data were prospectively collected in a dedicated database. Hypertension was defined as 
a systolic blood pressure (BP) > 140 mmHg and/or a diastolic BP > 90 mmHg or on-treatment with 
antihypertensive medications. The diagnosis of diabetes was based on previous history of diabetes 
treated with or without drugs, fasting glycaemia > 126 mg/dl or glycosylated haemoglobin > 6.5%. 
Hypercholesterolemia was defined as previous history of hypercholesterolemia, chronic treatment 
with any cholesterol-lowering agent at admission or fasting total cholesterol > 200 mg/dl.  
Biochemical measurements 
                                                                                                          
Blood samples were drawn at admission from patients undergoing elective (following a fasting period 
of 12 h) or urgent coronary angiography for main chemistry and genetic assessment. Glucose, 
creatinine, uric acid levels, blood cells count and lipid profile were determined by standard methods, 
as previously described (16). 25-hydroxyvitamin D measurement was performed by 
chemiluminescence method through LIAISON® Vitamin D assay (Diasorin Inc). The normal range for 
25-OH D3 levels in our laboratory is from 30 to 100 ng/ml, according to literature reference (17). 25-
hydroxyvitamin D inadequate levels were considered for levels < 10 ng/ml according to the US 
Endocrine Society guideline (17). 
CYP24A1 polymorphisms genotyping 
 
Using a commercially available kit (GenElute™ Blood Genomic DNA, Sigma Aldrich) genomic 
deoxyribonucleic acid (DNA) was isolated from 200 ml of the peripheral blood samples. The 
rs2762939 polymorphisms was studied using combined polymerase chain reaction (PCR) and 
restriction fragment length polymorphism technique. Following PCR conditions were used: 1.5 µl of 
genomic DNA were amplified in a mix containing MgCl2 [4 mM], deoxy nucleotides (dNTPs) mix [3%], 
5% dimethyl sulfoxide (DMSO), 0.25 µl/100 ml DNA polymerase (GoTaq® Hot Start Polymerase, 
Promega) and a primers mix [3%], (fwd; 5’-CCAAACGTGCTCATCATCTG-3’' and rev: 5’-
ATCAAACACATCCAGTGGAAA-3’), annealing temperature was settled at 54 °C. 
The polymorphism presence was evaluated by the pattern of length of restriction fragments after 
digesting PCR products by Sau96I- Cfr13I (Thermo ScientificBsuRI). 
In case of wild-type (G) allele, the enzyme recognised a restriction site resulting in products of 79 and 
45 base pairs, while a single fragment of 124 base pairs remained for mutated allele. The digestion 
product was analysed with electrophoretic run on high resolution agarose 2.15% TAE gel (Figure 1). 
Figure 1 Electrophoresis on High Resolution agarose gel after restriction of Polymerase Chain Reaction product with the 
enzyme Sau96I- Cfr13I  (TT= GG homozygotes, TNT= heterozygotes; NT= CC homozygotes) 
 
 
 
 
 
 
 
 
Coronary angiography 
                                                                                                           
Coronary angiography was routinely performed by the Judkins technique, preferring the radial 
approach, using 6-French right and left heart catheters. Quantitative coronary angiography was 
performed by two experienced interventional cardiologists (18) who had no knowledge of the 
TNT NT
TT
patients' genetic data, by an automatic edge-detection system (Siemens Acom Quantcor QCA, 
Erlangen, Germany). After the visual inspection of the coronary artery, the frame of optimal clarity 
was selected, showing lesion at maximal narrowing and arterial silhouette in sharpest focus. After 
the calibration of guiding catheter, the analysed arterial segment with coronary lesion was defined 
by moving the cursor from the proximal to the distal part of coronary artery to ensure adequate 
determination of reference diameter. We have measured minimal luminal diameter, reference 
diameter, percent diameter stenosis and length of the lesion. 
Significant CAD was defined as at least 1 coronary stenosis > 50%. Severe multivessel disease was 
defined as three-vessel disease and/or left main disease. In case of patients who had previously 
undergone percutaneous coronary intervention, even though no restenosis was observed, the 
treated vessel was counted as significantly diseased. In previously bypassed patients, native arteries 
and grafts were taken into account in the evaluation of extension of artery disease (number of 
diseased vessels).  
Statistical analysis     
                                                                                                                                
Statistical analysis was performed using SPSS 22.0 statistical package. Continuous data were 
expressed as mean + SD and categorical data as percentage. Analysis of variance and the chi-square 
test were used for continuous and categorical variables, respectively. Patients were grouped 
according to genetic status of CYP24A1, carriers of the mutated allele either in heterozygosis and 
homozygosis were considered together. Multivariate logistic regression analysis was performed to 
evaluate the relationship between genotype and coronary artery disease, after correction for 
baseline confounding factors that were entered in the model in block. Results were considered 
statistically significant for a two-tailed p < 0.05.   
  
 
RESULTS 
Table 1. Clinical characteristics according to CYP24A1 gene polymorphism rs2762939 
Baseline clinical characteristics GG 
(n=531) 
C-carriers 
(n=673) 
P value 
Age (mean±SD) 68.1 ± 11.3 67.7 ± 11 0.58 
Male Sex (%) 69.7 70.9 0.66 
BMI (mean±SD) 27 ± 4.4 27.3 ± 5.2 0.28 
Hypercholesterolemia(%) 55.6 55.2 0.86 
Diabetes mellitus (%) 36.0 38.5 0.37 
Renal failure (%) 19.2 21.8 0.37 
Active smokers (%) 21.4 24.0 0.59 
Hypertension (%) 71.7 74.6 0.29 
History of MI (%) 26.9 23.1 0.14 
Previous PCI (%) 36.7 30.8 0.36 
Previous CABG (%) 10.7 9.7 0.57 
Indication to angiography   0.93 
Stable angina/ silent ischemia (%) 28.5 25.5  
STEMI/ACS (%) 52.1 57.8  
Cardiomyopathy/ valvular 19.4 16.7  
Concomitant medications    
ACE inhibitors (%) 37.1 36.4 0.81 
ARB (%) 24.0 26.8 0.29 
Beta blockers (%) 55.2 52.6 0.38 
Nitrates (%) 33.2 33.4 0.99 
Statins (%) 59.0 51.9 0.01 
ASA (%) 64.3 61.1 0.25 
Clopidogrel (%) 19.9 18.5 0.55 
Calcium antagonists (%) 23.7 20.1 0.14 
Diuretics (%) 32.6 31.9 0.80 
Biochemistry parameters    
Platelets (10^6/ml; mean± SD) 225.2 ± 63.4 226.6 ± 70.9 0.73 
Haemoglobin (g/dl) 13.4 ± 1.7 13.4 ± 1.7 0.68 
WBC (10^3/ml;mean± SD) 8.07 ± 2.9 8.2 ± 2.9 0.43 
HDL cholesterol (mg/dL) 43.4 ± 13.2 42.7 ± 13.2 0.38 
LDL cholesterol (mg/dl) 91.7 ± 34.8 92.4 ± 35.5 0.71 
Glycaemia (mg/dL) 121.6 ± 45.7 124.2 ± 53.4 0.37 
Glycosylated haemoglobin (%) 6.3 ± 2.9 6.5 ± 2.9 0.51 
Creatinine (mg/dL) 1 ± 0.6 1 ± 0.5 0.88 
C reactive protein (mg/dL) 0.9 ± 2.02 1.2 ± 2.6 0.05 
Uric acid (mg/dl) 6.2 ± 3.7 6.4 ± 4.3 0.42 
CAD = Coronary Artery Disease; MI = Myocardial Infarction; PCI = Percutaneous Coronary Interventions; CABG = Coronary Artery 
Bypass Grafting; STEMI = ST-Elevation Myocardial Infarction; ACS = Acute Coronary Syndrome; CMD =Dilated Cardiomyopathy; 
LV = Left Ventricle; ACE = Angiotensin Converting Enzyme; ARB = Angiotensin Receptor Blockers;  
We included in our study 1024 patients, of whom 673 carried the C allele, 153(12.7%) in homozygosis. 
The frequency of the two-alleles, then, was: wild-type G: 66%; C-allele 34%; that respected the Hardy-
Weinberg equilibrium (p=0.15).  
Baseline clinical and demographic features are displayed in Table 1 and were well balanced between 
the two groups, but for a lower use of beta-blockers among the C-carriers (p=0.01) and higher levels 
of C-reactive protein (p=0.05).  
30.9% of the patients displayed hypovitaminosis D (< 10 ng/ml: 30% GG vs 31.5% C-carriers, p=0.64) 
and 21 (2.1%) of patients received vitamin D supplementation, with no difference according to 
genotype. 
The prevalence of CAD was not conditioned by CYP24A1 genetic status (78.7% GG vs 81.2% C-carriers; 
p=0.31; as in Figure 2).  
Figure 2 Polymorphism rs2762939 and prevalence of coronary artery disease (CAD). 
 
 
 
 
 
 
 
 
 
Similar results were obtained for severe CAD, as displayed in Figure 3 (29.1% GG vs 29.5% C carriers 
p=0.95). Results were confirmed at multivariate analysis, after correction for baseline differences 
(CAD: adjusted OR  [95% CI]= 0.71 [0.20-2.56], p=0.60 and;  severe CAD: adjusted OR [95% CI]= 0.87 
[0.73-1.04], p=0.13, respectively).  
Figure 3. Polymorphism rs2762939 and prevalence of severe coronary artery disease (CAD). 
 
 
 
 
 
 
 
 
However, as displayed in Table 2, the prevalence of coronary calcifications was significantly higher 
among GG homozygotes (p=0.005). 
 
Table 2. Angiographic characteristics according to CYP24A1 gene polymorphism rs2762939 
 
Angiographic features GG 
(n=940) 
C-carriers  
(n=1168) 
P value 
Left main disease (%)§ 8.1 8 0.99 
LAD (%)§ 54.7 58.8 0.174 
CX (%)§ 48.2 44.3 0.20 
RCA (%)§ 5.1 7.0 0.21 
Type C Lesion (%) 44.0 48.4 0.14 
Lesion length (mm) 22.2 ± 13.9 22.2 ± 13.9 0.92 
Percent stenosis (%)   2.9 ± 0.5 2.9 ± 0.6 0.23 
Reference Diameter (mm) 85.9 ± 13 86.2 ± 13 0.62 
Bifurcations (%) 20.8 22.0 0.52 
Calcifications (%) 18.5 14.0 0.005 
Chronic occlusion (%) 7.0 6.7 0.69 
Restenosis (%) 7.2 6.7 0.25 
Thrombus (%) 5.1 5.5 0.77 
TIMI Flow     0.14 
3 76.5 73.9  
2 1.9 4.7  
1 2.9 3.2  
0 18.7 18.2  
 
DISCUSSION 
 
This is the first study conducted so far to evaluate the relationship between CYP24A1 polymorphisms  
and the prevalence and extent of angiographically defined CAD in a large cohort of consecutive 
patients. The main finding is that this polymorphism is not associated with the prevalence and extent 
of coronary disease. However, the wild-type G allele, in homozygosis, significantly increases the 
prevalence of coronary calcifications.  
Accurate assessment of cardiovascular (CV) risk is essential for clinical decision-making, allowing the 
early identification and more aggressive treatment of those higher-risk subjects (19). Nevertheless, 
models and scores based on the well-established risk factors still leave a large gap in the prediction 
of cardiovascular ischemic events (20) and moreover, the addition of several biomarkers for the 
adequate stratification of the patients has offered so far inconclusive results (21).  
Vitamin D deficiency represents not only an emerging social problem, affecting over 1 billion of 
subjects worldwide (22), but also a relevant prognostic condition for the cardiovascular outcomes, 
being potentially involved in the pathogenesis of atherothrombosis (23). 
In the NHANES III study subjects with vitamin D levels < 20 ng/mL showed an increased occurrence 
of angina, myocardial infarction and heart failure (24), in the ARIC (Atherosclerosis Risk in 
Communities) (25), subjects in the lowest vitamin D quintile displayed an increased risk of stroke and 
also a recent meta-analysis including 8 cohorts of European/US patients confirmed an increased 
cardiovascular mortality for lower vitamin D levels (26).  In addition, similar results have been 
achieved in more recent cohort studies documenting an association between vitamin D deficiency 
and the angiographical prevalence of CAD or platelet reactivity, especially among subsets of patients 
at higher cardiovascular risk (27-29).  
Nevertheless, contrasting data have been reported so far on the potential benefits of vitamin D 
supplementation on cardiovascular outcomes, both in consequence of inadequate design of the 
studies and in presence of several factors modulating vitamin D levels and action (30,31). 
In fact, calcitriol preserves vascular system functions through several mechanisms, including the 
inhibition of intima-media thickening, enhancement of endothelial nitric oxide synthase, inhibition of 
macrophages activation and conversion into foam cells; prevention of calcium deposition in vessels,  
endothelial protection against advanced glycation end products (AGEs) and anti-thrombotic activity, 
effects that are mainly mediated by the interaction of the activated / hydroxylated 1,25(OH)2D with 
the vitamin D receptor (32).  
Therefore, genetic variants of vitamin D receptor and transporter and in the enzymes regulating the 
metabolism, hydroxylation and inactivation, of vitamin D have been suggested to interfere with the 
response to vitamin D. 
In particular, modifications in the function of the CYP24A1 hydroxylase, responsible for the 24-
hydroxylation and inactivation of calcitriol, have been proposed as modulating its levels and effect 
(33).  
The rs2762939 is a single nucleotide polymorphism (SNP) dependent from a CàG substitution in 
intronic position in the CYP24A1 enzyme. The C-allele is reported in 29% of the Caucasic population 
and, despite representing a synonymous mutation, it has been suggested to condition the protein 
synthesis, the expression of the enzyme and therefore its function. Previous reports, in fact, have 
linked this genetic variant with increased levels of vitamin D and 1,25(OH)2D (34,35).  
However only one study has so far addressed the cardiovascular effects of rs2762939 in 
cardiovascular disease, with promising results. In fact, Shen et al. (15) documented in 3 different 
cohorts of patients an association between this genetic variant and coronary artery calcifications 
(CAC quantity), as measured by electron beam computed tomography.  
Our study represents the first report addressing the role of this CYP24A1 polymorphism on coronary 
artery disease, evaluated at angiography.  
We documented in a large population of 1024 patients that the wild-type homozygotes display an 
increased rate of coronary calcifications, although the overall prevalence of CAD and severe CAD was 
not affected by the genetic status.  
Indeed, an opposite association of rs2762939 was documented for the levels of C-reactive protein, a 
marker that has been previously associated with cardiovascular risk and the progression of 
atherosclerosis. However, several other conditions can be responsible for non-specific raise in the 
levels of CRP, such as acute presentation or diabetic status, that were numerically more common in 
the ”C-allele” carriers, therefore providing potential explanation for this observation.  
However, our results support the previous data by Shen et al. and the reports derived in vitro, 
suggesting that higher calcitriol levels could prevent coronary calcification by reducing the 
accumulation of the lipid plaque, that constitutes the basis for calcium deposition and lowering the 
inflammatory response, preventing macrophages activation and vascular smooth-muscle cells 
activation (36).  
Therefore, present findings pave the way to further, larger studies, that should preferentially focus 
on the levels of calcitriol and the homeostasis of vitamin D activation, rather than on 25(OH)D. In fact, 
calcitriol, but not 25(OH)D, has been shown to improve endothelial function and survival in previous 
small studies (37,38).  
Study limitations 
 
Limitations of the present study include those inherent to any prospective but observational study. 
In particular, the differential distribution of cardiovascular risk factors, although non-statistically 
significant, could have partially represented a confounder, also accounting for the difference in the 
levels of C-reactive protein observed with genotype in our study. In addition, the low prevalence of 
C-allele homozygotes did not allow us to consider them separately from the heterozygotes, therefore 
reducing the power of our analysis. 
Moreover, we did not collect the data on 1,25(OH)2D in our patients, therefore we cannot provide a 
clear correlation between calcitrol levels, genetic status and the degree of coronary calcifications.  
In addition, the evaluation of the extent of CAD and of coronary calcium was performed at 
angiography, and we did not use additional methods of imaging as intracoronary ultrasound (IVUS) 
or optical coherence tomography, for the assessment of coronary calcification. 
Finally, we did not collect follow-up data, especially in patients undergoing coronary angioplasty, and 
thus cannot exclude an impact of this polymorphism of the progression of CAD, occurrence of acute 
MI and risk of adverse events after PCI.  
CONCLUSION 
 
This study showed in a large cohort of patients undergoing coronary angiography, that the 
polymorphisms rs2762939 of CYP24A1 is not associated with the prevalence and extent of CAD. 
However, the C-allele mutation carriage significantly lowers the rate of coronary calcifications.  
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ABSTRACT 
Background. Vitamin D deficiency is a pandemic affecting over 1 billion of subjects worldwide. Calcitriol 
(1,25(OH)2D) represents the perpetrator of the several systemic effects of vitamin D, including the anti-
inflammatory, antithrombotic and anti-atherosclerotic action potentially preventing acute cardiovascular 
ischemic events. Variability in the transformation of vitamin D into 1,25(OH)2D has been suggested to 
modulate its cardioprotective benefits, however, the determinants of the levels of calcitriol and their 
impact on the cardiovascular risk have been seldom addressed and were therefore the aim of the 
present study.  
Methods A consecutive cohort of patients undergoing coronary angiography for acute coronary 
syndrome (ACS) were included. The levels of 25 and 1,25(OH)2 D were assessed at admission by 
chemiluminescence immunoassay kit LIAISON® Vitamin D assay (DiasorinInc) and LIAISON® XL. 
Hypovitaminosis D was defined for 25(OH)D < 10 ng/ml, whereas 1,25(OH)2D deficiency for levels < 19.9 
pg/ml. 
Results We included in our study 144 patients, divided according to median values of 1,25(OH)2D (< or ≥ 
41.2 pg/ml). Lower calcitriol was associated to diabetes (p=0.05), renal failure (p=0.02), hypertension 
(p=0.001), use of calcium-antagonists (p=0.001), diuretics (p=0.007), higher creatinine (p=0.02), uric acid 
(p=0.04), and worse glycemic and lipid profile.  
37 patients (25.7%) had hypovitaminosis D, whereas 11 (7.9%) displayed calcitriol < 19.9 pg/ml (16.2% 
among patients with hypovitaminosis D and 4.9% with normal levels, p=0.06). 
The independent predictors of 1,25(OH)2D  deficiency were hypertension (OR[95%CI]=3.72[1.21-11.4], 
p=0.002), use of diuretics (OR[95%CI]=2.5[1.01-6.24], p=0.047), while negative predictor was the level of 
vitamin D (OR[95%CI]=0.930.89-0.98], p=0.008).  
Calcitriol levels, in fact, directly related with the levels of vitamin D (r=0.27, p=0.01), whereas an inverse 
linear relationship was observed with major inflammatory and metabolic markers of cardiovascular risk, 
(C-reactive protein: r=-0.27, p=0.002; uric acid: r=-0.24, p=0.03; homocysteine: r=-0.27, p=0.002; 
fibrinogen: r=-0.28, p=0.002), but for white blood cell count (r=-0.05, p=0.56) and Lp-PLA2 (r=-0.05, 
p=0.56).  
Conclusion The present study shows that among ACS patients, hypovitaminosis D is frequent, whereas 
being associated with sufficient levels of calcitriol in the majority of cases. We identified hypertension, 
use of diuretics and lower vitamin D as independent predictors of 1,25(OH)2D deficiency. Moreover, we 
documented a significant inverse relationship of calcitriol with C-reactive protein, uric acid, 
homocysteine, and fibrinogen, inflammatory and metabolic biomarkers strictly linked to cardiovascular 
risk 
Keywords:Vitamin D; calcitriol, Inflammation, Biomarkers, Acute Coronary Syndrome 
 
 
 
INTRODUCTION  
Vitamin D deficiency represents a rising social problem, affecting a huge part of the population of every 
age and ethnicity and even over 50% of healthy subjects (1).  
In the last years, evidence has emerged for several non-calcium dependent hormonal effects of vitamin 
D, linking its deficiency to increased mortality and to various chronic pathological conditions, as cancer, 
neurological disorders, as well as autoimmune and inflammatory diseases, hypertension, diabetes and 
atherothrombotic cardiovascular events (2,3).  However, vitamin D supplementation for the prevention 
of cardiovascular risk has not provided so far clear evidence of benefit, both due to the lack of well 
conducted dedicated trials and for the potential interference of several conditions that could modulate 
the response to the treatment (4,5). In particular, the systemic effects of vitamin D are mediated by the 
interaction of calcitriol (1,25(OH)2D) with vitamin D receptor (VDR), therefore genetic variants of the 
VDR, as much as factors regulating the transformation of vitamin D into its active hydroxylated hormone, 
calcitriol, have been addressed for defining the interindividual variability of the effect of vitamin D (6,7). 
Despite the evaluation of the precursor (25(OH)D) is generally preferred above the assessment of 
calcitriol levels, for its longer plasma half-life, previous studies have instead associated the levels of 
1,25(OH)2D to cardiovascular disease and worse prognosis, being more subject to transient variations in 
the context of acute events, as potentially in the settings of an acute coronary syndrome (ACS) (8,9). In 
addition, although the efficiency of calcitriol hydroxylation has been strictly related to renal function 
(10), representing the primary site for its transformation, extra-renal production of 1,25(OH)2D has also 
been documented (11), based on the identification of  the responsible 1α-hydroxylase enzyme in several 
tissues and districts, including the cardiovascular system, but whose exact role is largely undefined, 
especially in patients without severe renal disease. Aim of the present study was then to evaluate the 
determinants of calcitriol levels in a high-cardiovascular risk population of ACS patients and to evaluate 
their relationship with inflammatory biomarkers.  
METHODS 
We included consecutive patients undergoing coronary angiography for an acute coronary syndrome 
between November 2016 and January 2018 at the Azienda Ospedaliera-Universitaria, “Maggiore della 
Carità”, Novara, Italy. Informed consent was obtained from all patients before angiography.  
ACS was defined for Unstable Angina, NSTEMI or ST-segment elevation myocardial infarction, and 
therefore as patients were defined by the presence of chest pain at rest lasting > 20 minutes, with or 
without cardiac biomarkers elevation > ULN (respectively 0,04 µg/l for Troponin I and 5,00 µg/l for CK-
MB) or electrocardiographic modifications (either ST-segment depression or elevation >2 mm in at least 
2 contiguous leads or new LBB onset or T waves change).  
The protocol was approved by our local Ethical Committee and is in accordance to the Declaration of 
Helsinki statements. All demographic and clinical data were prospectively collected in a dedicated 
database. Hypertension was defined as a systolic blood pressure (BP) > 140 mmHg and/or a diastolic BP 
> 90 mmHg or on-treatment with antihypertensive medications. The diagnosis of diabetes was based on 
previous history of diabetes treated with or without drugs, fasting glycaemia > 126 mg/dl or glycosylated 
haemoglobin > 6.5%. Hypercholesterolemia was defined as previous history of hypercholesterolemia, 
chronic treatment with any cholesterol-lowering agent at admission or fasting total cholesterol > 200 
mg/dl.  
Biochemical measurement        
Blood samples were drawn at admission from patients undergoing elective (following a fasting period of 
12 h) or urgent coronary angiography. Glucose, creatinine, uric acid levels, blood cells count and lipid 
profile were determined by standard methods, as previously described (12). 25-hydroxyvitamin D and 
1,25(OH)2D measurement was performed by chemiluminescence method through LIAISON® Vitamin D 
assay (Diasorin Inc) and LIAISON® XL respectively. The normal range for 25-OH D3 levels in our 
laboratory is from 30 to 100 ng/ml, according to literature reference (13). 25-hydroxyvitamin D 
inadequate levels were considered for levels < 10 ng/ml according to the US Endocrine Society guideline 
(13). Calcitriol deficiency was defined for levels < 19.9 pg/ml according to the manufacturer.  
Lipoprotein-associated Phospholipase A2 (Lp-PLA2) was analyzed on ADVIA® 1800 Clinical Chemistry 
Analyzer (Siemens Healthcare Diagnostics). For the quantitative determination of Lp-PLA2 activity, the 
Diazyme Lp-PLA2 Activity Assay was utilized (Diazyme Laboratories, CA 92064, USA). Diazyme’s Lp- PLA2 
Activity Assay is an enzymatic assay. Lp-PLA2 in a sample hydrolyzes the acetyl group at the sn-2 position 
of phospholipids, 1- myristoyl-2-(4-nitrophenylsuccinyl)-sn-glycero-3-phosphocholine (MNP) to generate 
4-nitrophenyl group, a colorful product, which can be monitored spectrophotometrically at 405 nm. The 
activity of Lp-PLA2 in the sample is proportional to the absorbance increase. The instrument calculates 
the Lp- PLA2 activity of a sample by using the Diazyme Lp-PLA2 Activity Calibrator Set (REF DZ331A-CAL) 
to generate a calibration curve (14).  
Statistical analysis     
                                                                          
Statistical analysis was performed using SPSS 22.0 statistical package. Continuous data were expressed 
as mean + SD and categorical data as percentage. Analysis of variance and the chi-square test were used 
for continuous and categorical variables, respectively. Patients were grouped according to median 
values of 1,25(OH)2D. Forward conditional logistic regression analysis was performed to evaluate the 
independent predictors of calcitriol deficiency. Linear regression analysis was applied for evaluating the 
relationship of calcitriol with other continuous laboratory parameters. Results were considered 
statistically significant for a two-tailed p < 0.05.   
RESULTS 
We included in our study 144 patients, divided according to median values of 1,25(OH)2D (< or ≥ 41.2 
pg/ml).  
Major clinical and demographic features of the included population are displayed in Table 1.  
Table 1. Clinical characteristics according to median values of 1,25(OH)2D 
Baseline clinical characteristics < 41.2 pg/ml 
(n=72) 
≥41.2 pg/ml 
(n=72) 
P value 
Age (mean±SD) 69.6±12.6 67.4±11.3 0.28 
Weight (Kg±SD) 78±17 74±14.3 0.14 
Male Sex (%) 83.3 69.4 0.08 
BMI (mean±SD) 27.3±5.1 26.5±4.6 0.32 
Hypercholesterolemia(%) 50 63.9 0.13 
Diabetes mellitus (%) 33.3 18.1 0.05 
Renal failure (%) 26.4 9.7 0.02 
Active smokers (%) 23.6 2.2 0.63 
Hypertension (%) 84.7 59.7 0.001 
History of MI (%) 22.2 23.6 0.99 
Previous PCI (%) 26.8 26.4 0.99 
Previous CABG (%) 8.3 9.7 0.99 
ACS type (%)   0.14 
NSTEMI (%) 65.3 77.8  
STEMI (%) 34.7 22.2  
Left Main-Trivessel CAD (%) 52.5 44.6 0.46 
Concomitant medications    
ACE inhibitors (%) 27.1 25 0.85 
ARB (%) 30 19.4 0.17 
Beta blockers (%) 52.1 43.1 0.32 
Nitrates (%) 19.7 13.9 0.38 
Statins (%) 46.5 40.8 0.61 
ASA (%) 54.9 45.8 0.32 
Clopidogrel (%) 11.3 8.3 0.59 
Calcium antagonists (%) 36.6 12.5 0.001 
Diuretics (%) 42.3 20.8 0.007 
Vitamin D (%) 3.2 12.5 0.08 
Biochemistry parameters    
Platelets (10^6/ml; mean± SD) 218.9±68.3 237.1±37.5 0.11 
Haemoglobin (g/dl) 13±2.2 13.5±1.6 0.4 
WBC (10^3/ml;mean± SD) 9.8±4 9±2.6 0.15 
HDL cholesterol (mg/dL) 41.7±11.5 47.6±14.9 0.009 
LDL cholesterol (mg/dl) 98.3±34 112.3±40 0.03 
Glycaemia (mg/dL) 135.3±61 114.2±29.8 0.01 
HbA1c (%) 6.2±1.2 5.8±0.8 0.04 
25(OH)D (ng/ml) 16.2±10.2 20.4±10.8 0.02 
Creatinine (mg/dL) 1.1±0.6 0.87±0.3 0.02 
C reactive protein (mg/dL) 1.4±2.8 0.8±1.6 0.11 
Uric acid (mg/dl) 8.6±5.1 5.1±3.9 0.04 
CAD = Coronary Artery Disease; MI = Myocardial Infarction; PCI = Percutaneous Coronary Interventions; CABG = Coronary Artery Bypass 
Grafting; STEMI = ST-Elevation Myocardial Infarction; ACS = Acute Coronary Syndrome; CMD =Dilated Cardiomyopathy; LV = Left Ventricle; 
ACE = Angiotensin Converting Enzyme; ARB = Angiotensin Receptor Blockers;  
 
Table 2. Angiographic characteristics according to median values of 1,25(OH)2D 
Angiographic features < 41.2 pg/ml 
(n=166) 
≥41.2 pg/ml 
(n=149) 
P value 
Left main disease (%)§ 11.1 9.7 0.99 
LAD (%)§ 83.3 79.2 0.67 
CX (%)§ 59.7 51.4 0.40 
RCA (%)§ 59.7 58.3 0.99 
Type C Lesion (%) 54.8 51 0.57 
Lesion length (mm) 23.5±13.3 22.7±13.4 0.63 
Percent stenosis (%)   89.7±9.4 89.9±9.8 0.85 
Reference Diameter (mm) 3.1±0.5 3±0.6 0.12 
Bifurcations (%) 24.7 22.8 0.79 
Calcifications (%) 17.5 12.8 0.27 
Chronic occlusion (%) 16.4 16.1 0.99 
Restenosis (%) 5.6 6.1 0.99 
Thrombus (%) 9 11.4 0.58 
TIMI Flow     0.31 
3 75.3 69.1  
2 3 5.4  
1 1.2 0.7  
0 20.5 24.8  
 
Lower calcitriol was associated to diabetes (p=0.05), renal failure (p=0.02), hypertension (p=0.001), use 
of calcium-antagonists (p=0.001), diuretics (p=0.007), higher creatinine (p=0.02), uric acid (p=0.04), and 
worse glycemic and lipid profile. Angiographic characteristics did not substantially differ according to 
calcitriol median, as in Table 2. 
Figure 1 Prevalence of 25 and 1,25(OH)2D deficiency in included population 
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37 patients (25.7%) had hypovitaminosis D, whereas 11 (7.9%) displayed calcitriol < 19.9 pg/ml (16.2% 
among patients with hypovitaminosis D and 4.9% with normal levels, p=0.06), as in Figure 1. 
The independent predictors of 1,25(OH)2D  deficiency were hypertension (OR[95%CI]=3.72[1.21-11.4], 
p=0.002), use of diuretics (OR[95%CI]=2.5[1.01-6.24], p=0.047), while negative predictor was the level of 
vitamin D (OR[95%CI]=0.930.89-0.98], p=0.008).  
Figure 2 Linear relationship between 25 and 1,25(OH)2D 
 
 
 
 
 
 
 
 
 
 
Figure 3. Linear relationship between 1,25(OH)2D and C-reactive protein (3A, upper left), Homocystein (3B, upper right), 
Uric acid (3C, lower left) and Fibrinogen (3D, lower right). 
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Calcitriol levels, in fact, directly related with the levels of vitamin D (r=0.27, p=0.01, Figure 2), whereas 
an inverse linear relationship was observed with major inflammatory and metabolic markers of 
cardiovascular risk, (C-reactive protein: r=-0.27, p=0.002; uric acid: r=-0.24, p=0.03; homocysteine: r=-
0.27, p=0.002; fibrinogen: r=-0.28, p=0.002, Figure 3 A, B, and C), but for white blood cell count (r=-0.05, 
p=0.56) and Lp-PLA2 (r=-0.05, p=0.56), as in Figure 4A  and B respectively. 
Figure 4  Linear relationship between 1,25(OH)2D and white blood cells (4A, upper graph), lipoprotein-associated 
phospholipase A2 (Lp-PlA2, 4B, lower graph). 
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DISCUSSION 
 
This is the first study conducted so far to evaluate the clinical determinants of calcitriol levels and their 
relationship with inflammatory and cardiovascular risk biomarkers among ACS patients undergoing early 
invasive management. Despite we observed a significant independent association of 1,2(OH)2D with 
vitamin D levels, its deficiency was much more infrequent as compared to hypovitaminosis D, suggesting 
a potential “reserve” of vitamin D activation despite a deficiency of the substrate. Moreover, the 
prevalence of calcitriol deficiency was non-significantly lower in patients with 25(OH)D levels < 10 ng/ml, 
therefore suggesting the relevance of factors modulating the transformation of calcitriol and the 
importance of the direct dosing of the activated hormone rather that vitamin D. In addition, despite we 
included a high-risk ACS population, calcitriol related with several parameters mirroring the pro-
inflammatory status and cardiovascular risk, therefore suggesting a more complex disease and 
potentially worse long-term outcomes.  
Despite calcitriol represents the perpetrator of the effects of vitamin D, few studies have so far 
addressed the impact of its deficiency on the maintenance of the systemic homeostasis and in the 
pathogenesis of the several disorders linked to hypovitaminosis D (15,16). In fact, the relatively shorter 
plasmatic half-life of 1,25(OH)2D, only 12–36 h, in the human circulation as compared to its precursor 
has often been considered a barrier for its clinical application (17). However, 25(OH)D and 1,25(OH)2D 
cannot be considered equivalent measurements. Moreover, circulating calcitriol can be considered as 
being in a relatively steady state in healthy subjects (18) and, based on the development of more 
accurate methods for its measurement, raising interest has been addressed towards the consideration 
of the active form of vitamin D, and especially after the inconclusive results of the studies with 25(OH)D 
supplementation.  
In fact, in a recent study on dialysis patients no change in the intestinal absorption of Ca was obtained 
after 3months of 20,000 IU/week of cholecalciferol therapy before the normalisation of 25D and 
improvement of 1,25D levels (19). In further studies, no effect on bone metabolism parameters was 
evident following cholecalciferol supplementation of dialysis patients (20). 
A similar superiority of calcitriol above vitamin D has been documented in providing a cardioprotective, 
pleiotropic effect.  In a recent study, Zitterman et al (11) documented among over 500 patients with 
heat failure that lower calcitriol was associated with a higher rate of coronary artery disease and 
increased mid-term mortality. Moreover, in vitro study have shown that the active form of vitamin D 
induces a complex dual upregulation of endothelin and nitric oxide in cultured endothelial cells, reduces 
the expression of the angiotensin-1 receptor, improving endothelial function and preventing reactive 
oxygen species overproduction and downregulates hyperinsulinism and insulin resistance, lowering also 
the concentrations of various inflammatory markers including TNF-a, CRP and IL-6 in an overweight 
animal model (21-23).  
In addition, calcitriol has been shown to raises the levels of IL-12, that is relevant to macrophage activity 
and atherogenesis (24) and to modulate the coagulation cascade, increasing thrombomodulin and 
down-regulating tissue factor (25). However, its role in coronary thrombosis has never been assessed.  
Indeed, it could be hypothesized that the direct assessment of the levels of calcitriol could provide a 
more strict correlation with the pathogenesis of atherosclerotic lesions and their transient variations 
could favour plaques rupture, which represents the well-established causal mechanisms for acute 
coronary syndromes. Nevertheless, such hypothesis has never been considered so far in a dedicated 
clinical study.   
We firstly report the prevalence and predictors of calcitriol deficiency in a consecutive cohort of ACS 
patients undergoing early invasive management. We documented that lower calcitriol levels were 
associated with main established cardiovascular risk factors, and in particular with hypertension, 
diabetes and worse lipid profile, but also with renal function, and with a non-significant trend for 
presentation with ST-segment elevation MI. 
However, at multivariate analysis, only hypertension, use of diuretics and baseline levels of 25(OH)D 
emerged as independent predictors of calcitriol < 19.9 pg/ml, whereas no impact was played by age or 
gender, in accordance to the previous reports by Levin et al. (26) in an unselected cohort of 1814 
subjects. However, in this study, 1,25(OH)2D levels were related to diabetic status and parameters of 
renal function, as glomerular filtration and albumin-to-creatinine levels, although they recruited a large 
proportion of patients with kidney disease. In addition, oppositely to our results, the prevalence of 
calcitriol deficiency, in Levin et al. was much higher than calcitriol deficiency. However, about 35-40% of 
the study cohort was receiving a multivitamin supplementation, thus potentially accounting for the 
lower prevalence of hypovitaminosis D, as compared to our data.  
In fact, similarly to our conclusion, in a previous study over 500 patients with different degrees of renal 
dysfunction (from no chronic kidney disease-CKD to haemodialysis), Pasquali et al. (27) documented that 
both vitamin D levels, renal function and parathyroid hormone could modulate the efficiency of the 
hydroxylation of 25(OH)D to calcitriol. In fact, the lowest absolute values were observed in 
haemodyalisis patients without vitamin D deficiency, as these patients cannot be expected to 
substantially increase circulating levels of calcitriol from damaged kidneys simply because of substrate 
availability. In comparison, replete CKD patients exhibited a hydroxylation efficiency that, on average, 
did not significantly differ from HD patients, suggesting that the system is blunted in spite of some 
residual renal function.  
In our study, the rate of patients with inadequate calcitriol levels was less than 50% of the patients 
displaying sever vitamin D deficiency, suggesting the possibility to recruit a synthetic “reserve” for 
preserving the levels and function of the active hormone. In fact, the efficiency of 1,25(OH)2 D 
hydroxylation, however, can be rapidly increased by paracrine and auto-regulatory mechanisms, 
stimulating a local activity of the 1-α-hydroxylase in presence of high PTH, low calcium or inflammatory 
factors and cytokines. In fact, Pasquali et al. (27) showed in subjects with no CKD, that the efficiency of 
calcitriol production was linearly related to the levels of substrate, but became an exponential increment 
when 25(OH)D levels declined below 20 ng/ml. On the contrary, such reserve was not observed in 
presence of renal dysfunction, confirming that kidney activity and vitamin D levels represent the 
principal determinants of calcitriol production.  
Nevertheless, in our study, use of diuretics, but not the levels of creatinine or the history of CKD 
emerged as independent predictors of 1,25(OH)2D deficiency. Indeed, vitamin D transformation is a 
tubular process, therefore being potentially less related with the levels of renal clearance and 
glomerular filtration rate (GFR). Consistently, in a previous report, Prince et al. (28) documented a 
preserved calcitriol synthesis despite GFR reduction in patients with moderate CKD. 
Similar conclusion was also reached by Pasquali et al., (27) showing an exponential growth in vitamin D 
hydroxylation, among haemodyalisis patents, underlining the potential role of extra-renal production of 
calcitriol.  
Such paracrine activation of vitamin D could play an intriguing role in preventing the acute inflammatory 
processes leading to the instabilization and rupture of a plaque and therefore to the onset of acute 
coronary syndromes. In fact, we observed a direct linear correlation of calcitriol with several biomarkers 
of the inflammatory and thrombotic process, even in a selected population of high-risk ACS patients, 
where an elevation of such parameters could be expected in all patients. However, 1,25(OH)2D did not 
correlate with the levels of Lp-PlA2 and white blood cells, suggesting that in the acute context the anti-
inflammatory effect of vitamin D could be elicited more on the humoral that on the cellular-mediated 
response. Nevertheless, such hypothesis certainly needs further confirmations in larger dedicated 
studies, aiming at the exact definition of the pathophysiological mechanisms and the prognostic 
relevance of our observations, potentially offering new targets for the treatment and risk stratification of 
ACS patients. 
 
Study limitations 
 
The first limitation to our study is the relatively low sample of included patients, therefore, being more 
subject to any difference due to the non-randomized design of the study. In particular, the differential 
distribution of cardiovascular risk factors could have partially represented a confounder.  
Moreover, we restricted our analysis to higher-risk ACS patients, in absence of a control population. 
Nevertheless, such recruitment was planned on purpose, since no data have been so far reported for 
calcitriol in an acute cardiovascular setting, representing on the contrary a subset of patients that could 
achieve the greatest benefits from the restoration of the cardioprotective effects of vitamin D.  
Finally, we did not collect follow-up data, especially in patients undergoing coronary angioplasty, and 
thus cannot exclude an impact of 1,25(OH)2D of the progression of CAD, recurrent cardiovascular events 
and the risk of adverse events after PCI.  
CONCLUSION 
 
The present study shows that among ACS patients, hypovitaminosis D is frequent, whereas being 
associated with sufficient levels of calcitriol in the majority of cases. We identified hypertension, use of 
diuretics and lower vitamin D as independent predictors of 1,25(OH)2D deficiency. Moreover, we 
documented a significant inverse relationship of calcitriol with C-reactive protein, uric acid, 
homocysteine, and fibrinogen, inflammatory and metabolic biomarkers strictly linked to cardiovascular 
risk 
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Conclusions and future perspectives 
 
Vitamin D deficiency represents a pandemic social problem affecting over 1 billion of people 
worldwide, although its clinical relevance is still largely neglected (1).  
Several studies have documented that the maintenance of adequate levels of vitamin D offers 
benefits in terms of survival, quality of life and for the maintenance of “house-keeping” homeostatic 
processes in different organs and tissues, including the cardiovascular system (2,3).  
However, the exact threshold for the definition of the optimal levels of vitamin D required for the 
achievement of the cardioprotective effects is still debated. In fact, while a circulating 25(OH)D < 10 
ng/ml is universally accepted as a severe deficiency, it is still unclear whether the cut-off for 
sufficiency is to be settled at 20 or 30 ng/ml (4).  
In Chapter 2, we documented a progression of the risk of coronary artery disease with the lowering 
of vitamin D levels, although its prevalence and extent were significantly enhanced only for patients 
with levels < 10 ng/ml. 
In addition, the present thesis documented, in Chapter 8, that, even among subjects with vitamin D 
< 10 ng/ml, yet the levels of circulating active hormone could be preserved, therefore pointing at the 
superiority of the direct evaluation of calcitriol levels rather than vitamin D precursors.  
Indeed, the definition of the complex regulatory mechanisms responsible for the homeostasis of 
vitamin D levels still needs further clarification (5). In fact, both genetic factors and several clinical 
conditions, despite not conditioning the measured circulating 25(OH)D, can modulate its 
bioavailability and effects, therefore translating into cardiovascular consequences.  
In Part 3 in fact, we showed that both genetic variants of vitamin D binding protein (VDBP) and of the 
24-α hydroxylase responsible for vitamin D inactivation (CYP24A1), can be held responsible for the 
clinical manifestations of vitamin D deficiency, against comparable levels of vitamin D.  In fact, carriers 
of the G allele of rs7041 of VDBP; a variant associated with an enhanced binding of the vitamin to its 
transport-protein, displayed an increased thrombogenicity despite dual antiplatelet therapy (DAPT), 
only when this genetic status was associated with vitamin D deficiency.  
Moreover, variability in the levels of the active hormonal form, calcitriol, could affect coronary 
calcifications and the inflammatory status. In Chapter 7, in fact, we showed that the wild-type 
genotype for rs2762939 of CYP24A1 were associated with coronary calcifications, potentially 
mediated by an increased inactivation of 1,25(OH)2D due to a higher enzymatic activity. In addition, 
in Chapter 8, we reported that activated vitamin D in ACS patients could be conditioned not only by 
the levels of its precursor, but also by other factors as hypertension and renal dysfunction.  Indeed, 
the kidney represents the principal site of activation of vitamin D, and mainly at a tubular level, 
therefore explaining the reason for our positive association with the use of diuretics rather than with 
serum creatinine, instead representing a glomerular process. In addition, hypertension, by increasing 
the wall shear stress, could favor the induction of the pathway responsible for the paracrine 
production of calcitriol in the endothelium of the whole arterial system, thus increasing its circulating 
levels. On the contrary, an extremely focused vascular damage, as in case of an acute coronary 
syndrome, being dependent on the instabilization of a single atherosclerotic lesion, could also 
stimulate  a local production of 1,25(OH)D, that could nevertheless result in too modest variations to 
be apparent at a systemic level. Such hypothesis, as much as the common pathogenesis of the 
spectrum of acute coronary events, could certainly explain our observation of similar levels of 
1,25(OH)2D in different ACS types.  
Therefore, present thesis directly points out at calcitriol as a marker of cardiovascular disease and a 
potential new target for a pharmacological approach to cardiovascular prevention.  
In fact, 1,25(OH)2D, being linked to a pro-inflammatory and pro-thrombotic status and to vascular 
wall degeneration and remodeling, could represent an early predictor of cardiovascular risk, even in 
subjects without established coronary atherosclerosis.  
In addition, the definition of the optimal levels of calcitriol for cardiovascular prevention could allow 
to optimize the therapy and to define which patients could mostly benefit from its supplementation, 
and especially for high-cardiovascular risk patients, as in the context of an ACS.  
Indeed, the trials conducted so far on the topic are largely inadequate for answering to this issue, not 
being powered for the evaluation of cardiovascular endpoints and often failing in the restoration of 
adequate levels of vitamin D (6,7). The ongoing the VITamin D and OmegA-3 TriaL (VITAL) trial (8) will 
certainly shed more light on the topic, by enrolling 25,874 men and women across the U.S. taking 
daily dietary supplements of vitamin D3 or omega-3 fatty acids for the reduction of the risk of cancer, 
heart disease, and stroke.  
Nevertheless, the majority of the studies were conducted with inactive 25(OH)D, then being subject 
to a differential activation and potentially not resulting in sufficient hormonal levels. In fact, the 
studies with direct calcitriol replacement have being conducted so far only in patients with renal 
failure, providing promising results, (9,10) that however, will certainly deserve confirmations in a 
more general population.  
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